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ABSTRACT 
Impaired platelet function may lead to bleeding in inherited or acquired 
diseases, but can also be drug-induced and thus helpful to prevent severe 
thrombotic events such as heart attack or stroke. The response to anti-platelet 
agents can differ widely between individuals from good to very poor 
(„resistant“). The light transmission aggregometry (LTA) is still considered to be 
the „gold standard“ method for testing platelet (dys)function, but it has several 
limitations. Because of the growing interest in testing the efficacy of anti-platelet 
therapy, new methods were developed with the aim to simplify usage and make 
them available as point-of-care-instruments. 
In this study four whole blood methods were evaluated in comparison to the 
LTA, focusing on the resistance to the anti-platelet agents Aspirin and 
Clopidogrel.  
Three groups of individuals were tested with the LTA, whole blood impedance 
aggregometry (WBA, Multiplate®), the vasodilatator-stimulated phosphoprotein 
(VASP) phosphorylation assay (VASP assay), cone and plate(let) analyzer 
(CPA, Impact™ and Impact-R™), and platelet function analyzer (PFA-100®, in-
vitro-bleeding-time). Normal ranges were obtained from 39 healthy individuals. 
In 32 cardiologic patients on dual anti-platelet therapy the response to Aspirin 
and Clopidogrel was tested with arachidonic acid (AA) and ADP (1,6mM and 
11µM in the LTA). In the third group (patients with platelet disorders) platelet 
function was additionally assessed with the agonists epinephrine, ristocetin and 
collagen.  
In reference to the obtained normal values response to Aspirin was found in 
between 61 to 100% of cardiologic patients. Only the WBA data correlated 
significantly with LTA data (r=0,461;p≤0,01). A high concordance of test results 
was achieved between LTA and Impact™ > Multiplate®. Data indicating 
response to Clopidogrel varied widely between methods (39,1 -  87%). Strong 
correlations between the LTA data and the Impact™ (r=-0,793; p≤0,0001), 
Multiplate® (r=0,571; p≤0,001), Multiplate® HS (r=0,671; p≤0,0001) and Impact-
R™ (r=-0,546; p≤0,003) were found. Best concordance in response was found 
with Impact-R™. Impact™ and Impact-R™ were only correlating significantly 
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with ADP (r=0,790; p≤0,0001). The highest frequency of abnormal data was 
seen with the PFA-100® in patients with suspected bleeding disorders. 
Multiplate® and LTA obtained data were similar in these patients. 
 
In conclusion, our data suggest that in comparison with the LTA, WBA and CPA 
are the most adequate methods for testing anti-platelet drug response.  
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ZUSAMMENFASSUNG 
Eine Beeinträchtigung der Thrombozytenfunktion kann bei ererbten oder 
erworbenen Krankheiten zu Blutungen führen, sie kann aber auch gezielt durch 
Medikamente herbeigeführt werden und dadurch bei der Vorbeugung von 
ernsthaften thrombotischen Erkrankungen wie Herzinfarkt oder Schlaganfall 
mitwirken. 
Das Ansprechen auf anti-thrombozytäre Medikamente kann individuell von gut 
bis sehr schlecht (“resistent”) stark variieren. Die Aggregometrie nach Born 
(LTA) gilt nach wie vor als “Goldstandard” unter den Methoden zur Messung der 
Thrombozyten(dys)funktion, unterliegt allerdings einigen Einschränkungen. 
Zunehmendes Interesse, die Wirksamkeit antithrombozytärer Medikamente zu 
testen, führte zur Entwicklung neuer Methoden, die durch ihre vereinfachte 
Handhabung auch als „point-of-care“ Geräte einsetzbar sein sollen. 
In dieser Studie wurden vier Vollblut-Methoden der LTA gegenübergestellt und, 
mit Hauptaugenmerk auf das Nicht-Ansprechen auf die Medikamente Aspirin 
und Clopidogrel, evaluiert. 
 
Drei Patientengruppen wurden mit LTA, Vollblut-Impedanzaggregometrie 
(WBA, Multiplate®), dem Vasodilatator-stimulated phosphoprotein (VASP) 
Phosphorylierungs assay (VASP assay), dem cone and plate(let) analyzer 
(CPA, Impact™ und Impact-R™), und platelet function analyzer (PFA-100®, in-
vitro-bleeding-time) getestet. Normalwerte wurden mit Blutproben von 39 
gesunden Personen ermittelt. Bei 32 kardiologischen Patienten, unter 
Behandlung sowohl mit Aspirin als auch Clopidogrel, wurde das Ansprechen 
auf diese Medikamente mit Arachidonsäure (AA) und ADP (1,6mM und 11µM in 
der LTA) getestet. Die dritte Gruppe (Patienten mit Thrombozyten-
Funktionsstörungen) wurde zusätzlich mit den Agonisten Epinephrin, Ristocetin 
und Collagen getestet.  
In Bezug auf die ermittelten Normalwerte wurden bei kardiologischen Patienten 
zwischen 61 und 100% Ansprechen auf Aspirin festgestellt. Eine signifikante 
Korrelation (r=0,461; p≤0,01) zeigte sich nur zwischen den Ergebnissen der 
LTA und der WBA. Eine hohe Übereinstimmung der Ergebnisse wurde 
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zwischen LTA und Impact™ > Multiplate® erreicht. Diejenigen Werte, die auf ein 
Ansprechen auf Clopidogrel hindeuten, wiesen eine große Streuung zwischen 
den Methoden auf (39,1 -  87%). Starke Korrelationen traten zwischen der LTA 
und dem Impact™ (r=-0,793; p≤0,0001), Multiplate® (r=0,571; p≤0,001), 
Multiplate® HS (r=0,671; p≤0,0001) und Impact-R™ (r=-0,546; p≤0,003) auf. Die 
beste Übereinstimmung ergab sich mit dem Impact-R™. Impact™ und Impact-
R™ wiesen nur mit ADP eine signifikante Korrelation (r=0,790; p≤0,0001) auf. 
Bei den Patienten mit Verdacht auf Blutungsstörungen wurde das häufigste 
Vorkommen anormaler Werte mit dem PFA-100® beobachtet. Die am 
Multiplate® ermittelten Werte waren bei diesen Patienten den LTA-Werten am 
ähnlichsten. 
 
Zusammenfassend legen unsere Ergebnisse nahe, dass, verglichen mit der 
LTA, die geeignetsten Methoden zur Beurteilung des Ansprechens auf 
antithrombozytäre Medikamente die Vollblut-Impedanzaggregometrie und der 
cone and plate(let) analyzer sind. 
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I. INTRODUCTION 
Platelets play an important role in primary hemostasis to support bleeding arrest 
in case of vessel wall damage. Impaired platelet function may lead to bleeding 
complications in inherited or acquired diseases, but can also be helpful in 
preventing thrombosis formation, if drug-induced.   
Atherosclerotic plaques can activate platelets, which consequently form blood 
vessel occluding clots (thrombosis) leading to acute complications like heart 
attack or stroke. In high risk patients anti-platelet drugs, such as Aspirin and 
Clopidogrel, can inhibit different pathways of platelet function, preventing severe 
events. The response to these agents can differ widely between individuals, 
from good response to non-response or “resistance”.  
Different methods for diagnosing and monitoring platelet dysfunctions have 
been developed. In recent years more interest is put on monitoring the efficacy 
of anti-platelet therapy and measuring platelet activity to detect resistant 
patients. The wide range of available tests suggests evaluation to determine the 
appropriate method. 
1. PLATELETS AND PRIMARY HEMOSTASIS 
(Harrison P, George JN, Gawaz, Silbernagl, Schmidt Thews) 
Platelets (thrombocytes) are small, discoid shaped, anucleated cells which 
derive from megacaryocytes and circulate at between 150 – 450 x 109 /l blood 
in the closed vessel system for about 10 days. 
In case of vessel wall damage blood can escape into the surrounding tissue. 
Through a complex process of thrombocyte-activity and interactions between 
platelets and soluble plasma components the injured vessel wall can be 
occluded which consequently leads to stable bleeding arrest. It is classified into 
primary and secondary hemostasis. Primary hemostasis is characterized 
through adhesion, activation (including a shape change) and aggregation of 
platelets leading to formation of a primary platelet-rich clot (white thrombus). In 
secondary hemostasis the plug is modified through activation of the coagulation 
cascade into a consolidated fibrin-rich thrombus (red thrombus). 
1. ADHESION 
Under normal conditions circulating platelets remain in a dormant stage and do 
not stick to the endothelial cells of the vessel wall. In areas of damage platelets 
adhere to the now exposed subendothelial structures in a first contact phase, 
initialized by the release of von Willebrand factor (vWF) which is secreted by the 
subendothelium. The platelet membrane bound receptor for the vWF 
(glycoprotein (GP) Ib-V-IX) recognizes this released perivascular vWF and 
allows the adhesion to the vessel wall (Figure 1).  
Stabilization of the adhesion is provided through further membrane receptors for 
collagen, fibronectin and laminin. A rapid first contact and furthermore a quick 
formation of stable conditions is necessary due to present high shear forces to 
the vessel wall.  
subendothelial matrix
Ib Ib
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Ia/IIa
VI/Fcγ
IIb/IIIa*
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adhesion
activation
blood flow
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Figure 1: Adhesion and acrivation of platelets in primary hemostasis (with kind permission of 
Beate Kehrel) 
2. ACTIVATION and SECRETION 
During the process of adhesion platelets simultaneously become activated 
(Figure 1). Morphological and functional changes are initialized particularly 
through binding of the platelet collagen receptor to the subendothelial collagen 
and the formation and release of other soluble agonists such as adenosine 
diphosphate (ADP, induces activation and aggregation) and thrombin (most 
powerful activating agent) or epinephrine, which bind to their specific platelet 
surface receptors and induce the formation of second messengers (Figure 2). 
Once an intracellular Ca2+ concentration threshold is exceeded, platelets 
change into a spherical shape and form pseudopods through polymerization of 
G-actin and formation of F-actin filaments (shape change). The increased 
platelet surface supports the interaction of platelets with each other as well as 
with plasma components and therefore the closure of the damage in the vessel 
wall.  
su
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Figure 2: Shape change and secretion of platelets in primary hemostasis (with kind permission 
of Beate Kehrel) 
The secretion of the agonists from secretory granules (dense and α- granules)  
reinforces adhesion through different mechanisms such as release of Ca2+ or 
the activation of fibrinogen receptors in the GP IIb-IIIa complex. This leads to an 
activation and recruitment of still resting platelets and a subsequent aggregation 
with already adhering platelets via GP IIb-IIIa receptors. The GP IIb-IIIa 
complex also plays an important role in the so called spreading process, which 
is the final step in adhesion.  
Additionally activated platelets produce arachidonic acid (AA) which leads to the 
formation of thromboxane A2 (TXA2). This reinforces the activation process and 
also acts as a vasoconstrictor and therefore supports clot formation by slowing 
down the blood flow.  
PMNL
subendothelial matrix
endothelial 
cell-
endothelial 
cell
collagen
monocyte
aggregation + recruitment of leukocytes
 
monocyte
PMNL
subendothelial matrix
endothelial 
cell
collagen
fibrin formation on thrombus
endothelial 
cell
 
Figure 3: Aggregation and subsequent thrombus formation leading to bleeding arrest (with kind 
permission of Beate Kehrel) 
3. AGGREGATION 
Through platelet activation and therefore exposure and activation of GP IIb-IIIa 
complex on the platelet surface binding sites for fibrinogen get available. The 
process is strongly dependent on the presence of Ca2+ and fibrinogen which are 
released into the direct surrounding of the growing thrombus. In a first step 
(primary aggregation) platelets only form loose, reversible fibrinogen bridges 
(Figure 3). After a time lag of seconds to minutes degranulation of agonists 
(ADP, TXA2) ensues, which results in an irreversible connection between 
platelets (secondary aggregation). When the aggregation process and thus the 
formation of a platelet-rich thrombus is finished, primary hemostasis is 
completed. The following activation of the coagulation cascade in secondary 
hemostasis finally leads to complete bleeding arrest. 
Among other functions adhesion, shape change, secretion and aggregation in 
primary hemostasis can be summarized as “platelet function”.  
13 
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2. IMPAIRMENT OF PLATELET FUNCTION 
1. DRUG INDUCED IMPAIRMENT 
Under physiological conditions the hemostatic clot is limited to the injured area 
and therefore does not affect the blood flow and the supply of the surrounding 
tissue (Gawaz, 2001). At sites of ruptured atherosclerotic plaques platelets get 
activated and form clots (thrombosis). Occlusions of the blood vessel through 
thrombosis blockade the blood flow with subsequent damage of the surrounding 
tissue and result in acute complications such as heart attack or stroke (Ruggeri, 
2002). Platelets not only play a role in the formation of thrombosis but also in 
the genesis of atherosclerosis (Ruggeri, 2002). There is also evidence that 
increased platelet activity is determined genetically in patients with coronary 
disease (Shields et al, 2002).  
The multifaceted processes in primary hemostasis open the pharmacological 
possibility to selectively inhibit pathways through specific targeting (Ruggeri, 
2002) for appropriate treatment and prevention of atherothrombosis. Through 
combination of different anti-platelet drugs inhibiting different pathways, such as 
the major ADP and TXA2 pathways, better outcomes can be achieved than with 
single inhibition (Cattaneo, 2004).  
a) Aspirin 
The most commonly used agent to decrease the risk of atherothrombotic 
diseases is acetylsalicylic acid (Aspirin). 
i. Mechanism of Aspirin action  
The effect of acetylsalicylic acid (Aspirin) is mainly based on the permanent 
inactivation of cyclooxygenase-1 (COX-1) activity (Roth and Majerus, 1975 ; 
Patrono et al, 2004) (Figure 4). COX-1 is one of two isoenzymes that catalyzes 
the transformation of AA into prostaglandin synthetase PGH2 (Patrono et al, 
2004) which is further metabolized to TXA2 by the enzyme thromboxane 
synthetase (Fitzgerald and Maree, 2007). The molecular mechanism of the 
inhibition of COX-1 activity by AA is based on the acetylation of a serine residue 
(Ser530). Because TXA2 is largely a COX-1 dependent product, it is very 
sensitive to the effect of Aspirin (Patrono et al, 2004) and therefore, if 
inactivated, ineffective as a vasoconstrictor and for reinforcement of platelet 
aggregation. Because platelets cannot generate new COX the effect of Aspirin 
lasts for their life-time (Michelson et al, 2005).  
 
Figure 4 : Schematic illustration of the pharmacological sites of Aspirin action (Cattaneo, 2004) 
As platelets are highly involved in acute atherothrombotic events, anti-platelet 
drugs play an important role in the therapy of linked diseases. In patients with 
earlier cardiovascular or cerebrovascular events, Aspirin can reduce the risk of 
a myocardial infarction, stroke or vascular death by about 25% (Antithrombotic 
Trialist´s Collaboration, 2002). For acute events a loading dose of minimum 
150mg are required, whereas for long-term use sufficient anti-platelet effects 
can be achieved with low doses (75 – 150mg) (Antithrombotic Trialist´s 
Collaboration, 2002).  
b) Clopidogrel 
Clopidogrel (Iscover®, Plavix®) is a thienopyridine that irreversibly inhibits 
platelets and is mainly used in combination with Aspirin.  
i. Mechanism of  Clopidogrel action 
During secretion platelets release ADP from their storage granules which binds 
to the purinergic receptors P2Y1 and P2Y12, therefore reinforcing aggregation at 
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regions of endothelial lesions (Gawaz, 2001). The ADP-receptor antagonist 
Clopidogrel, once transformed through hepatic metabolism into its active form 
(Cattaneo 2004, Gawaz, 2001), inhibits the platelet membrane (Figure 5) ADP 
receptor P2Y12 (Cattaneo, 2004) thereby indirectly inhibiting the binding of 
plasmic fibrinogen to GP IIb-IIIa complex and thus aggregation (Sharis et al, 
1998; Gawaz, 2001). A dose of 75mg per day leads to a significant inhibition of 
platelets from the second day on and constant levels of activity are found after 4 
-7 days (Gawaz, 2001). In a large multicenter trial, where Clopidogrel (75mg/d) 
was compared to Aspirin (325mg/d) in patients at risk for atherosclerotic 
vascular disease after stroke, myocardial infarction (MI) or peripheral artery 
disease, a relative risk reduction for ischemic stroke, MI or vascular death of 
8,7% could be found (CAPRIE Steering Committee,1996). It could also be 
shown that patients with coronary artery disease (CAD) after percutaneous 
intervention and stenting benefit from inhibition of two aggregation pathways 
such as through a dual anti-platelet therapy with Clopidogrel and Aspirin 
(Cattaneo, 2004; Metha et al, 2001; Steinhubl et al, 2002).  
 
Figure 5 : Schematic illustration of the pharmacological sites of Clopidogrel action (Cattaneo, 
2004) 
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c) Anti-platelet drug resistance 
In the last years the existence of „resistance“ or “non-response” to anti-platelet 
drugs was discussed, because expected effects in patients were not always 
achieved. This phenomenon is still unclear in many aspects and the evaluation 
of response to these drugs remains an active field of research (Spectre et al, 
2005). Furthermore clarification on the definition of the term “resistance” is 
needed. As Spectre et al (2005) and Michelson et al (2005) indicate it could be 
based on whether the clinical outcome or on laboratory test results. Cattaneo 
(2004) suggests a usage of the term „resistance“ in case of the inability of a 
drug to hit its pharmacological target because it is unable to reach it or in case 
of target alteration, but would not consider all patients with atherothrombotic 
events despite intake of anti-platelet drugs as “resistant”. This “clinical 
resistance”, defined mainly in connection with Aspirin, should better be termed 
as “treatment failure” (Cattaneo, 2004; Patrono, 2003; Michelson et al, 2005). It 
also has to be taken into account that Aspirin and Clopidogrel only inhibit 
specific pathways, whereas in the genesis of thrombosis many agonists are 
involved, which makes it impossible for the anti-platelet drugs to prevent all 
events (Fitzgerald and Maree, 2007).  
Based on laboratory tests, resistance to anti-platelet drugs is also not 
necessarily given when high residual platelet reactivity is found, especially when 
the tests used are not specific to the effect of the agent. However, non-specific 
tests are helpful to detect hyperreactivity, although only specific ones can 
determine whether it is caused by a weak pharmacological effect of the drug or 
not (Cattaneo, 2007).  
Furthermore, as the dosage of drugs is often determined by the population 
response, selecting a treatment where risk and benefit is balanced will also 
include individuals who will not respond to the chosen dose (Fitzgerald and 
Maree, 2007)  
i. Aspirin resistance  
In patients receiving Aspirin a wide variability in response is found and as 
different laboratory tests including different cut-off values are used, the 
frequency of non-responders varies in studies (Cattaneo, 2007). Patrono et al 
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(2004) report about recurrent thrombotic events in about 10 - 20% of Aspirin 
treated patients with arterial thrombosis (during long-term follow up). Campbell 
and Steinhubl (2005) report in a review of 11 studies using non-specific tests 
that rates varied between 5,5 to 61%. Other studies found resistance in 1 – 
1,7% when measuring thromboxane B2 (TXB2) levels, or below 1% in case of 
testing AA induced platelet aggregation, which leads to the assumption that 
Aspirin resistance appears extremely rare, when using specific tests (Cattaneo, 
2007).  
Different reasons that are eventually responsible for the non-responsiveness to 
Aspirin, such as reduced bioavailability or too low dosage respectively, an 
accelerated platelet turnover, the presence of less sensitive COX-1 variants or 
transient resistance caused through coronary surgery are summarized by 
Cattaneo (2007). Furthermore simultaneous intake of other drugs can influence 
the effect of Aspirin (Patrono, 2003). But the most plausible and most frequent 
reason for resistance or poor response is lack of compliance as Frelinger et al 
(2006) describe. Additionally Gurbel et al (2007) found out, that in patients with 
diabetes a higher dose of Aspirin is needed to achieve similar results as in non-
diabetic patients.  
As described above it is unclear whether the definition of “resistance” should be 
based on laboratory measurements. Concerning Aspirin it is possible to 
determine non-responders by conducting functional tests or biochemical 
measurement of serum TXA2 (Spectre et al, 2005). “Resistance” based on early 
platelet aggregation tests was difficult to interpret considering the fact that 
platelet aggregation tests have not been found useful to describe the 
pharmacology of Aspirin (Patrono, 2003). Based on Cattaneos definition 
(Cattaneo, 2004) Aspirin resistance is given when the COX-1 dependent TXA2 
production cannot be inhibited (Cattaneo, 2007).  
ii. Clopidogrel resistance   
Although using specific tests a wide variability in response to Clopidogrel was 
found, including a significant amount of low responders and results of up to 
about 30% cases indicating non-response (Aleil et al, 2005; Grossmann et al, 
2004; Gurbel et al, 2003). 
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Most likely these differences occur due to variability in the metabolization of the 
pro-drug caused by genetic variance of the activating enzyme cytochrome 
P450, whereas polymorphisms in the ADP-receptor seem not to be associated 
to interindividual differences in response (Cattaneo, 2007; Fitzgerald and 
Maree, 2007). Furthermore other reasons for interindividual variability could 
result from interactions with other drugs, low bioavailability through different 
absorption or wrong dose in relation to BMI, or from already existing differences 
in response of platelets to ADP (Cattaneo, 2007; Fitzgerald and Maree, 2007). 
The found variability in response seems to indicate differences in bioavailability 
and not “resistance” of the ADP-receptor as defined by Cattaneo (Fitzgerald 
and Maree, 2007; Cattaneo, 2007).   
d) Monitoring of anti-platelet drugs 
Grumann et al (2007) suggest monitoring and individual adjustment of anti-
platelet therapy as a good possibility for optimizing individual inhibition to 
identify resistant patients and therefore prevent recurrent events or to prevent 
bleeding through individual overdosing. Some studies have demonstrated that 
MACE (major adverse cardiac events) in cardiovascular diseases can predicted 
through platelet function tests, but these assays first have to be studied in large 
clinical trials before being regularly used in clinical care (Michelson, 2004).  
2. INHERITED PLATELET DYSFUNCTIONS 
In inherited platelet disorders bleeding occurs varying from spontaneous, mostly 
mucocutaneous bleeding to excessive traumarelated bleeding in milder forms 
(Nurden and Nurden, 2008; Keeney and Cumming, 2001)  
a) Von Willebrand Disease 
The von Willebrand disease (vWD) is characterized through impaired adhesion 
because of qualitative and quantitative deficiency of the vWF (Ruggeri and 
Zimmerman, 1987; Platelet Perspectives® http://www.plateletperspectives.com, 
2007). About twenty subtypes have been described, the actual classification 
defines six different types (Ruggeri and Zimmerman, 1987; Sadler, 1994). Type 
1 is the most common type of vWD and occurs in 70-80% of all cases 
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(allaboutbleeding.com; http://www.allaboutbleeding.com, 2008; HUMATE-P, 
http://www.humate-p.com, 2009). It is associated with partial quantitative vWF 
deficiency which results in mild to moderate bleeding tendency (Sadler, 1994; 
Keeney and Cumming, 2001). Type 2 is subclassified into 2A, 2B, 2M and 2N 
and characterized through a qualitative defect of the vWF (Keeney and 
Cumming, 2001). In type 2B thrombocytopenia and giant platelets can be found 
(Nurden and Nurden, 2007). Type 3 is described as a severe quantitative 
disorder because of very low or absent platelet and plasma vWF (Keeney and 
Cumming, 2001). Additionally a platelet type is described which is similar to 
type 2B vWD (Nurden and Nurden, 2008).  
All forms of vWD are autosomal dominant in inheritance except type 2N and 3 
which are passed on autosomal recessive. As Gill et al (1987) described, a 
correlation of the AB0 blood group system with the occurrence of vWD was 
shown.  
In rare cases a defect of vWF can also be acquired (acquired von Willebrand 
syndrome (AVWS)) (Eikenboom et al, 2007, Kumar et al 2003, Velik-Salchner 
et al, 2008). It is mostly associated with underlying diseases such as lympho- 
and myleoproliferative disorders, malignancies, hypothyroidism, immunologic or 
cardiovascular diseases, but also induced by drugs and autoimmune diseases 
(Federici et al. 2000; Velik-Salchner et al, 2008; Federici et al., 2004; Mohri 
2003). vWD and AVWS show quite similar laboratory “phenotypes” and 
bleeding symptoms, which makes it difficult to differentiate in clinical practice 
(Eikenboom et al, 2007).   
b) Bernard-Soulier syndrome and Glanzmann thrombastenia  
Bernard-Soulier syndrome (BSS) and Glanzmann thrombastenia (GT) are also 
inherited diseases where bleeding symptoms occur due to platelet function 
abnormalities in primary hemostasis, but are found quite rarely. Such patients 
were not studied. 
3. DISEASE ASSOCIATED IMPAIRMENT 
Abnormal platelet function can be acquired through anti-platelet drugs as 
described above but also through different diseases such as diabetes mellitus, 
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liver disease, immune-mediated diseases or uremia and end stage renal failure 
(ESRF) respectively. Since only 5 patients with ESRF were included in this 
study, the other disease-associated platelet function impairments are not further 
discussed.   
a) Platelet function disorder in uremia 
In patients with uremia (and ESRF) both hemorrhagic diathesis and thrombosis 
tendencies can be found (Hörl, 2006). Hemorrhagic diathesis in these patients 
is associated with both thrombocytopenia and impaired platelet function. 
Thrombocytopenia, quite likely because of early destruction of platelets 
(Himmelfarb et al, 1997) is found in 16-55% of uremic patients (Hörl, 2006). 
However, bleeding tendencies are mainly caused by impaired platelet adhesion 
and aggregation. Adhesion is reduced because of reduced GP Ib levels 
(Himmelfarb et al, 1998; Sloand et al, 1991). Though normal levels of GP IIb 
and GP IIIa are found (Walkowiak et al, 1994), aggregation is impaired through 
inadequate conformational changes in the GP IIb-IIIa complex, which is caused 
quite likely because of uremic toxins (Gawaz et al, 1994). Furthermore a 
functional cyclooxygenase defect and reduced production of TXA2 were found 
in patients with renal failure (Remuzzi et al, 1983). Receptors for vWF and 
fibrinogen can also be affected through inappropriate membranes in dialysis, 
which leads to interaction defects between platelets and with the vessel wall 
(Hörl, 2006). 
As mentioned above also increased tendencies for thrombosis were found in 
patients with renal failure. Increased platelet aggregation and hypercoagulation 
associated with higher levels of erythrocyte-platelet-aggregates (Sirolli et al, 
2001) or platelet microparticles (Ando et al, 2002) were found compared to 
healthy individuals.  
The use of anti-platelet drugs to prevent shunt-thrombosis in patients with 
ESRF is nor recommended as they do not reduce the risk of thrombosis, but 
rather lead to increased bleeding tendencies (Kooistra et al, 1994; Kaufman et 
al, 2003). 
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3. PLATELET FUNCTION TESTING     
Many tests have been developed to identify causes of abnormal bleeding and to 
monitor pro–haemostatic therapy in case of increased risk of bleeding. Apart 
from these major applications platelet function tests are furthermore used to 
predict thrombosis by identifying platelet hyperfunction and to monitor the 
efficacy of antiplatelet therapy (Rand et al., 2003; Harrison, 2005). Due to the 
large number and variety of platelet dysfunctions there is no current platelet 
function test that is 100% sensitive (Harrison, 2005).  
The oldest way to test platelet function is the in vivo method bleeding time (BT), 
developed by Duke in 1910 and later modified by Ivy and regarded as the most 
useful screening test for platelet function until the early 1990s (The British 
Society for Haematology, 1988). BT is the measured period of time for bleeding 
to stop after inducing a lesion, usually into the forearm. The test was refined 
through using specific templates for making standardized cuts (Harrison, 2005), 
but it is no longer recommended due to its non-specificity and “lack of clinical 
correlations” (Michelson et al, 2006).  
In the following years a series of in vitro methods became available. Besides 
the light transmission aggregometry (LTA), which was presented in the early 
1960s by Born and is still considered to be the “gold standard”, new instruments 
were developed in the last years, with the aim to be simpler in use, available as 
point-of-care (POC) instruments (and not only in specific laboratories) and less 
invasive. Platelet function can be tested in whole blood, which requires no more 
sample preparation, shorter assay times and smaller amounts of blood. 
Furthermore with some methods platelet function can be tested under close to 
physiological conditions including shear forces. Additionally the new methods 
are trying not to be limited to specialized operators and to be more cost-
effective. 
1. ESTIMATION OF PLATELET FUNCTION IN PLATELET RICH PLASMA  
i. LIGHT TRANSMISSION AGGREGOMETRY  
Through the invention of the in vitro method LTA in the 1960s the diagnosis of 
platelet function defects could be notably improved. The method is based on the 
measurable change of turbidity in platelet rich plasma when platelet aggregation 
is induced through agonists (Figure 6). The biggest advantage of platelet 
aggregometry is that the aggregation of platelets can be measured in vitro in a 
GP IIb-IIIa dependent manner, which is the most important function of platelets 
(Michelson et al, 2006).  
Different studies have shown that measurement of platelet aggregation with 
LTA can detect platelet hyperreactivity in healthy individuals (Yee et al, 2005) or 
predict the risk of recurrent MACEs in patients (Matetzky et al, 2004; Gum et al, 
2003; Frere et al, 2007). Furthermore it is an appropriate method for diagnosing 
inherited platelet function defects (Budde, 2002). 
 
Figure 6: Light transmission aggregometry principle 
However, LTA has many disadvantages, as platelets are not in their 
physiological milieu which includes red cells and leukocytes, the system runs 
under low shear conditions, and formation of aggregates only after addition of 
agonists, time consuming centrifugation steps, requirement of large amount of 
blood samples, requirement of specialized operators, and cost (Harrison et al, 
2007; Shenkman et al, 2008; Michelson, 2004). Additionally, there is still a lack 
in standardization between laboratories including used concentrations of 
agonists or if platelet-count-adjustment in platelet-rich plasma (PRP) is 
recommended or not (Cattaneo et al, 2007; Linnemann et al,2008 ). 
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2. WHOLE BLOOD SYSTEMS 
a) LOW SHEAR SYSTEMS 
i. IMPEDANCE AGGREGOMETRY (WHOLE BLOOD AGGREGOMETRY) 
In the whole blood impedance aggregometry (WBA) agonists are added directly 
into whole blood and platelet aggregation is measured through the change of 
impedance between electrodes, where platelets adhere and aggregate 
(Cardinal and Flower, 1980). Therefore no time consuming centrifugation steps 
are necessary. Further development of the instrument (Multiplate® -Multiplate® 
Platelet Function Analyzer, Figure 7) now allows simultaneous measurements 
through multiple channels and a computerized quality control through multiple 
independent sensor units in the test cells (cuvettes) (Calatzis, 2007). The test 
procedure is well standardized through software prompt and an automatic 
pipette, which provides better reproducibility and makes the device quite simple 
in use. As disposable cuvettes are available the assay is now less laborious. In 
comparison to other new tests it is rather expensive (due to disposable 
cuvettes) (Michelson, 2004). High sensitivity to the effects of Aspirin and 
Clopidogrel could be shown (von Pape et al, 2007, Sibbing et al, 2008) as well 
as good applicability in perioperative management for quick diagnose and 
therapy of platelet function disorders (Görlinger et al, 2007) with the Multiplate®. 
As it is an open system it is used for these clinical purposes (monitoring of 
platelet inhibitors, assessment of perioperative platelet function disorders or 
screening for platelet function defects like GT or BSS) but can also be modified 
for research application (http://www.Multiplate®.net).  
firm adhesion and 
aggregation of platelets 
on the sensor surface 
enhances the electrical 
resistance between the 
2 sensor wires
> principle of Multiplate® analysis
 
Figure 7: Multiplate® and its test principle (www.Multiplate®.net) 
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ii. VASP PHOSPHORYLATION FLOW CYTOMETRIC ASSAY 
The vasodilatator-stimulated phosphoprotein (VASP) phosphorylation assay 
(VASP assay) is used to test the inhibition of the ADP-receptor P2Y12 and 
therefore is a very specific method for the evaluation of the efficacy of agents 
that inhibit the ADP-receptor such as Clopidogrel (Aleil et al, 2005) (Figure 8). 
Advantages of this test are, that it is directly dependent on the P2Y12 receptor 
and that only a small sample volume is required; on the other hand, the method 
is relatively cost-intensive, sample preparation and a specialized operator are 
needed (Michelson, 2004) and although the method protocol is well 
standardized differences in the calculation of PRI (platelet reactivity index) lead 
to variable results (Siller-Matula et al, 2009). The test has shown good results 
for detecting reduced platelet inhibition and therefore is useful in predicting stent 
thrombosis or MACEs after stenting (Bonello et al, 2007; Barragan et al, 2003). 
Furthermore, there is evidence that it is not sensitive to inherited P2Y12 
deficiency because normal results were obtained (Cattaneo, 2007). 
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 Modified from Cattaneo in PLATELETS (Michelson, 2nd ed, 2007)
Figure 8: Schematic illustration of the VASP assay principle (modified from Cattaneo in Platelets 
(Michelson AD, 2nd ed, 2007) 
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b) HIGH SHEAR SYSTEMS 
These devices were developed with the attempt to simulate the in vivo 
processes during vessel wall damage, platelet function is tested under high 
shear conditions (Harrison et al, 2007)  
i. CONE AND PLATE(LET) ANALYZER 
In 1997 Savion and Varon presented the first instrument to test whole blood 
platelet adhesion and aggregation on a plate coated with extracellular matrix 
(Varon et al, 1997) which was replaced through polystyrene plates to make it 
commercially available (Impact™(-R), Figure 9) (Harrison, 2005). With the cone 
and plate(let) analyzer (CPA) platelet adhesion and aggregation can be tested 
under close to physiologic conditions by inducing high shear on the polystyrene 
well. It is possible to test platelet function in a screening test as well as agonist 
induced platelet aggregation (Savion and Varon, 2006; Shenkman et al, 2008). 
It is a simple and rapid method where only a small sample of whole blood is 
required (Michelson, 2004; Harrison et al, 2007), otherwise the system is not 
well standardized yet and results are depending relatively strong on the 
operator. This method, requiring platelet activation and the presence of 
fibrinogen, vWF and their receptors, can be used to assess platelet function 
disorders (Shenkman et al, 2000) such as vWD or GT (Varon et al, 1997). 
There is evidence for the usefulness of the CPA for monitoring the function of 
transfused platelets in patients with BSS or other severe platelet disorders 
(Panzer et al, 2007). The Impact-R™ may also be a useful instrument for the 
evaluation of platelet function under platelet harvesting or storage procedures 
(Jilma-Stohlawetz et al, 2008). Furthermore, it is a good method for monitoring 
the effects of anti-platelet drugs (Shenkman et al, 2008; Spectre et al, 2005). In 
a relatively small study, Matetzky et al could detect poor response to 
Clopidogrel in a significant percentage of STEMI (ST-segment-elevation acute 
myocardial infarction) patients with the Impact™ (Matetzky et al, 2004). 
 Figure 9: Impact-R™ (www.diamed.com) and test principle (www.matis-medical.com) 
ii. PLATELET FUNCTION ANALYZER  
With the platelet function analyzer (PFA-100®) the in-vitro-bleeding time can be 
measured (Figure 10). The first instrument was presented in 1985 (Kratzer and 
Born, 1985) and was further developed to the now available PFA-100®. The 
instrument simulates high shear in disposable cartridges. Whole blood is 
aspirated through a small aperture in a membrane that is coated with collagen 
and either epinephrine or ADP, platelets get activated and form a hemostatic 
clot. The time until occlusion of the aperture is measured. The device is easy in 
use, no sample preparation is needed, the assay time is short and furthermore it 
is characterized through good precision and reliability (Michelson, 2004; 
Cattaneo, 2007; Jilma, 2001). Many studies have tested the clinical applicability 
(Jilma, 2001). The assay has found to be sensitive to vWD and other severe 
platelet disorders such as GT or BSS, but not very sensitive to mild, inherited or 
drug induced platelet dysfunctions (Hayward et al, 2006). This can be due to the 
high sensitivity of the method to different variables influencing platelet 
aggregation, such as platelet count, platelet reactivity to collagen and plasma 
vWF (Cattaneo, 2004) and is therefore not a reliable assay for testing the 
efficacy of Aspirin and Clopidogrel (Cattaneo, 2007)   
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 Figure 10: PFA-100® device (http://diagnostics.siemens.com) and schematic illustration of a test 
cartridge (http://www.freepatentsonline.com/6702987.html) 
28 
 
29 
 
II. AIM OF THIS STUDY 
There are not many studies that compare more than two methods for testing the 
platelet function in patients on dual anti-platelet therapy, with inherited and 
acquired diseases or other bleeding complications.  
The different laboratory methods described above (WBA (Multiplate®), VASP 
phosphorylation assay, CPA (Impact™ and Impact-R™), and the platelet 
function analyzer (PFA-100®) were evaluated in comparison to the “gold 
standard” method LTA in their ability to detect resistance to Aspirin and 
Clopidogrel.  
Furthermore the feasibility of these methods for the assessment of suspected 
bleeding disorders was tested. 
  
30 
 
III. MATERIALS and METHODS 
1. STUDY POPULATIONS 
Three groups of study populations (healthy individuals and patients) were 
tested. The study was approved by the Ethics Committee of the Medical 
University of Vienna. All participants were informed about the purpose of the 
study and gave informed consent. 
1. Reference population  
(Population 1) 
39 healthy volunteers, aged 18 to 73 years, were tested to obtain normal ranges 
for each parameter. All subjects were asked about their smoking habits, intake 
of garlic, fish oil preparations, olive oil within the last 24 hours and blood group 
(if known) (Table 1).  
Females were additionally asked about the use of hormonal contraceptives. 
One person had a gestagenic implant, all other positive persons reported to 
take oral contraception (Table 1). 
The information was recorded through standardized questionnaires. 
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Table 1: Characteristics of reference population 
REFERENCE POPULATION   
n 39 
Male/Female n 15/24 
Age (median) 32,5 
Smoking (%) 33,4 
Intake of fish oil preparations, olive oil, garlic (%) 12,8 
Contraceptive (hormonal) (%) 12,9 
Bloodgroup n 
0+ 10 
0- 2 
A+ 16 
A- 1 
B+ 4 
B- 1 
AB+ 3 
AB- 0 
 
Subjects were recruited at the Clinical Department of Blood Group Serology, 
Medical University of Vienna and selected according to the following criteria.  
Inclusion criteria:  -    Equal or greater than 18 years of age 
- Apparently healthy 
- Platelet count between 120 to 400 G/l 
Exclusion criteria: -    Any medication, except contraceptive pills 
- Pregnancy 
- History of bleeding or thromboembolic complications 
- Platelet count <120 G/l or > 400G/l 
- Haemoglobin <10g/dl and/or haematocrit <30%     
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2. Patients on anti-platelet therapy  
(Population 2) 
32 Patients on therapy with Aspirin and Clopidogrel or Aspirin only were 
analyzed. Subjects, both males and females, aged between 41 and 89 years, 
were asked about their smoking habits, intake of garlic, fish oil preparations, 
olive oil within the last 24 hours and blood group (if known) (Table 2). Given 
information and the enacted daily dose of Aspirin and Clopidogrel respectively, 
were recorded through standardized questionnaires. 
Table 2: Characteristics of patients on anti-platelet therapy 
ANTI-PLATELET THERAPY POPULATION   
n 32 
Male/Female n 27/5 
Age (median) 63 
Smoking (%) 6,2 
Intake of fish oil preparations, olive oil, garlic 
(%) 3,1 
Medication 
Aspirin (100mg) 8 
Aspirin (100 mg) + Clopidogrel (75 mg) 22
Aspirin (100 mg) + Clopidogrel (150 mg) 2 
Bloodgroup n  
0+ 8 
0- 0 
A+ 5 
A- 1 
B+ 6 
B- 1 
AB+ 4 
AB- 0 
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All patients were recruited at the Department of Internal Medicine II and 
selected according to the following criteria. 
 
Inclusion criteria:  -    Equal or greater than 18 years of age 
- Receiving Aspirin or Clopidogrel or both 
Exclusion criteria: -     Abnormal Impact™ screening test 
-     Pregnancy 
- History of bleeding complications 
- Platelet count <120 G/l 
- Haemoglobin <10g/dl and/or haematocrit <30%     
-  
3. Patients with vWF deficiency or platelet disorders  
(Population 3) 
 
This study population consisted of two persons with vWD (one was tested 
twice), 12 other patients with bleeding complications recruited from the Clinical 
Division of Haematology and Haemostaseology, Department of Internal 
Medicine I , and 5 patients with end stage renal failure recruited at the Division 
of Nephrology and Dialysis. Males and females, aged between 25 and 89, were 
included and asked about their smoking habits, intake of garlic, fish oil 
preparations, olive oil within the last 24 hours and blood group (if known). Given 
information was recorded through standardized questionnaires (Table 3). 
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Table 3: Characteristics of patients with platelet disorders 
PLATELET DISORDER POPULATION   
n 20 
Male/Female n 5/15 
Age (median) 44,5 
Smoking (%) 15 
Intake of fish oil preparations, olive oil, garlic (%) 15 
Bloodgroup n 
0+ 12 
0- 0 
A+ 4 
A- 0 
B+ 2 
B- 0 
AB+ 0 
AB- 0 
 
 
Additionally vWF-Antigen (vWF: AG), vWF-Multimers, vWF Ristocetin-CoFactor 
(vWF: RiCoF) and Fibrinogen values were recorded, if known.  
Patients were selected according to the following criteria. 
Inclusion criteria:  -    Equal or greater than 18 years of age 
- Confirmed vWD or other bleeding complications   
Exclusion criteria: -     Pregnancy 
- Platelet count <120 G/l 
- Haemoglobin <10g/dl and/or haematocrit <30%     
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The blood samples of the three study populations were analyzed between the 
end of June 2007 and January 2008. 
2. BLOOD SAMPLING 
A maximum of 12 ml buffered citrated blood (3,8 % Na-citrate) and 4ml of 
heparin blood were obtained from each person by venipuncture using a 21 
gauge needle and evacuated tubes containing sodium citrate and heparin 
respectively (Vacuette® Blood Collection Set and tubes, Greiner Bio-one, 
Kremsmünster, Austria). 
Blood was drawn with minimum stasis, avoidance of foam formation and mixed 
gently after collection. The first few drops were discarded.  
All samples were analyzed after 30 to 180 minutes after collection.   
WHOLE BLOOD COUNT 
A whole blood count (WBC) was performed with a Beckman/Coulter T540 
Haematology Analyzer® (Beckman Coulter Inc., Fullerton, CA) for each 
individual, mainly to get information about platelet number, haematocrit and 
haemoglobin because these factors influence the sample analysis results. 
Additionally, white and red blood cell count and mean cell volume (MCV) were 
recorded. 
3. SAMPLE ANALYSIS 
1. LIGHT TRANSMISSION AGGREGOMETRY  
The LTA method is based on the change in turbidity in PRP while platelets 
aggregate. This process is induced by added agonists.  
For measurement a cuvette containing PRP is placed in an apparatus where a 
light beam passes the sample. As the agonist is added and platelets aggregate, 
the optical density in the sample decreases and more light passes. The 
increase in aggregation is recorded as a platelet aggregation curve, which 
provides information about the percentage of aggregation (maximum amount of 
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change in light transmission), slope of the aggregation (in % change of 
aggregation per minute) and the area under the aggregation curve within a 
defined period (start- and endpoint). Platelet poor plasma (PPP) is used as a 
reference value (100% aggregation). 
a) PREPARATION OF PRP and PPP 
After blood collection samples rested for at least 10 minutes before they were 
stored uncapped in a tilted position (45°) for 20 minutes. PRP was subsequently 
obtained by centrifugation of citrated blood (3,8% sodium citrate) for 10 minutes 
at 150g (850 rpm) and room temperature without break (Rotixa / AP centrifuge, 
Hettich, Tuttlingen, Germany). 
PRP was removed with a pipette with a large inner diameter (to avoid activation 
of platelets) and PPP was produced by further centrifugation at 1200g (3000 
rpm) for 5 minutes at room temperature (Rotanta / AP centrifuge, Hettich, 
Tuttlingen, Germany) and a following centrifugation of the obtained PPP for 5 
minutes at 13.000 rpm (13.000g) (Heraeus Biofuge fresco, Kendro Laboratory 
Products, Hanau, Germany).  
PRP platelet count was measured with the Beckman/Coulter T540 
Haematology Analyzer®. Tubes containing PRP were stored uncapped until 
aggregation was tested. 
b) AGGREGOMETRY 
In this study a Chrono-Log Model 490-4D optical four channel aggregometer 
(Chrono-Log Corporation, Havertown, USA) was used for performing the LTA. 
The associated AGGRO/LINK® Software for Windows was used on the 
connected computer (IBM) and results were printed out on an external printer.  
To analyze agonist induced platelet aggregation, 225µl of PRP were pipetted 
into a cuvette (with spacer on bottom and stir bar inside) and preheated to 37°C 
for at least 6 minutes. Subsequently 25µl of Agonist (Table 4) were added for 
the various tests (AA-LTA, ADP-LTA, TRAP-LTA, EPI-LTA, RISTO-LTA H and 
L, COL-LTA). The change in light transmission was measured for 5 minutes. If 
necessary, agonists were diluted with PBS to achieve the required final 
concentration. Startpoint (addition of agonist) was defined manually, results 
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were calculated by the software and printed out. Maximal aggregation was used 
for analysis. 
Table 4: LTA-Agonists and final concentrations  
LTA 
AGONIST ALIQUOT for 0,25ml FINAL CONCENTRATION 
AA 25µl 1,6mM 
ADP 25µl 11µM 
TRAP-6 6,25µl (+ 18,75 PBS) 25µM 
EPI 2,5µl (+22,5µl PBS) 5,5µM 
RISTO H 25µl 1,6mg/ml 
RISTO L 12,5µl (+12,5µl PBS) 0,8mg/ml 
COL 25µl 11µg/ml 
(AA=arachidonic acid, ADP= adenosine diphosphate, TRAP=thrombin receptor activating 
peptide, EPI=epinephrine, RISTO=ristocetin H=high, L=low, COL=collagen)  
 
All individuals were tested with AA-LTA, ADP-LTA and TRAP-LTA. In addition, 
population 1 and 3 were tested with EPI-LTA and RISTO-LTA H, and population 
3 also with RISTO-LTA L and COL-LTA. 
2. IMPEDANCE AGGREGOMETRY  
(WHOLE BLOOD AGGREGOMETRY, WBA) 
To test the samples with WBA the Multiplate® (Dynabyte, Munich, Germany) 
device was used.  
The principle of this “multiple platelet function analyzer” is based on the change 
of electrical resistance between two electrodes. The activated platelets adhere 
to and aggregate on the metal sensor wires. 
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The wires are located in disposable test cells. Four electrodes form two 
independent sensor units. Two curves are assessed because the instrument 
detects the impedance change of each sensor unit separately. Platelet 
aggregation is recorded continuously and transformed to arbitrary “aggregation 
units” (AU). The provided software calculates parameters; area under the 
aggregation curve (AUC), velocity (maximum slope of the curve), and 
aggregation (AU) are mean values of the parameters determined with each 
curve. Five channels and a fully automated pipette can be used for multiple test 
procedures. The apparatus is equipped with an internal Windows XP based 
computer system and test results are automatically saved on the system´s hard 
disk.  
In this study 300µl of gently mixed Heparin blood were added to 300µl of 
prewarmed saline 0,9% in the test cell and incubated for 3 minutes at 37°C. 
Subsequently defined aliquots of agonists (Table 5) were added for the various 
tests (ASPItest (AA), ADPtest, ADPtest HS, TRAPtest, RISTOtest H, RISTOtest 
L). A PTFE-coated stirring magnet provided mixing of the sample. The change 
of the electrical resistance between the wires after addition of the agonist was 
recorded for 6 minutes measuring time. 
Table 5: Multiplate®-Agonists and final Concentrations  
MULTIPLATE® 
AGONIST  ADDITION to 0,6ml 
FINAL 
CONCENTRATON 
AA  20µl 0,5mM 
ADP 20µl 6,4µM 
ADP HS 20µl ADP + 20µl PGE1 6,4µM + 9,4nM (PGE1) 
TRAP-6 20µl 32µM 
RISTO H 50µl 0,77mg/ml 
RISTO L 12µl 0,2mg/ml 
(AA=arachidonic acid, ADP= adenosine diphosphate, ADP HS=ADP high sensitive, 
TRAP=thrombin receptor activating peptide, RISTO=ristocetin H=high, L=low)  
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Following tests were performed:  
Population 1: ASPItest, ADPtest, ADPtest HS, TRAPtest, RISTOtest H.  
Population 2: ASPItest, ADPtest, ADPtest HS, TRAPtest 
Population 3: ASPItest, ADPtest, TRAPtest, RISTOtest H +L.  
3. VASP PHOSPHORYLATION FLOW CYTOMETRIC ASSAY  
The vasodilatator-stimulated phosphoprotein (VASP) phosphorylation assay 
(VASP assay) is used to test the inhibition of the ADP-receptor P2Y12 and the 
platelet responsiveness to Clopidogrel respectively. The phosphorylation of 
VASP is regulated by the cAMP (cyclic adenosine monophosphate) cascade, 
which is activated through PGE1 (prostaglandin E1) and inhibited by ADP.  
In this study the VASP phosphorylation was determined using a standardized 
flow cytometric assay (Platelet VASP; BioCytex, Marseille, France), which is an 
adaption of the method of Schwarz et al (Schwarz et al, 1999). Blood samples 
(3,8% sodium citrate-anticoagulated whole blood) were incubated first with 
PGE1 alone or with PGE1 + ADP. A subsequent fixation was followed by 
permeabilization of the platelets and labelling with a primary monoclonal 
antibody against serine 239-phosphorylated VASP (clone 16C2) or its isotype, 
followed by a secondary fluorescein isothiocyanate (FITC)-conjugated 
polyclonal goat-antimouse antibody (Table 6). All steps were performed at room 
temperature, while incubation tubes were stored without light. Finally, 1000µl of 
diluent-reagent were added and samples were stored at 2-8° C until analysis 
within 120 minutes.  
Table 6: VASP assay   
VASP ASSAY 
 Tube 1 Tube 2 Tube 3 Incubation
Incubation with PGE1 / 
PGE1 + ADP 
5µl WB 
5µl PGE1 
5µl WB 
5µl PGE1 + 
ADP 
5µl WB 
5µl PGE1 + 
ADP 
10 min 
RT, dark 
Fixation 
5µl fixative 
reagent 
5µl fixative 
reagent 
5µl fixative 
reagent 
5 min 
RT, dark 
Permeabilization & VASP-
Antibody / Isotypic Control 
5µl VASP-Ab 5µl VASP-Ab 5µl Control 
5 min 
RT, dark 
Staining with FITC-IgG & 
CD61-PE 
5µl staining 
reagent 
5µl staining 
reagent 
5µl staining 
reagent 
5 min 
RT, dark 
(WB = whole blood) 
For determination of the mean fluorescence intensity (MFI) a FACSCalibur flow 
cytometer (Becton Dickinson, BD, San Jose, CA) was used. The device was 
calibrated daily with standard BD Calibrate beads containing specific amounts 
of “mean equivalent soluble fluoresceine molecules” in combination with the 
CELLQuestPro software. The platelet population was identified by its forward 
and side scatter distribution, a total of 10.000 events were gated and analyzed 
for MFI. 
Platelet reactivity was expressed as PRI calculated as shown in Figure 11. The 
ratio is expressed as mean percentage of platelet reactivity, inversely correlated 
with the Clopidogrel treatment efficiency. 
Figure 11: Platelet Reactivity Index (T1, T2, T3 = Tube 1, 2, 3) 
MFIc(PGE1) = MFIc(T1) = MFI (T1) – MFI (T3) 
MFIc(PGE1+ADP) = MFIc(T2) = MFI (T2) – MFI (T3) 
PRIVASP [%] = [(MFIc(PGE1) – MFIc(PGE1+ADP)) / MFIc(PGE1)] x 100 
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The VASP assay was performed with all patients on therapy with Clopidogrel. 
Normal samples were also analyzed in parallel as normal controls. 
4. CONE AND PLATE(LET) ANALYZER  (CPA) 
a) Impact-R™ 
With the Impact-R™ device (DiaMed, Cressier, Switzerland) platelet function, 
effectiveness of anti-platelet therapy and other acquired and congenital 
abnormalities in primary haemostasis can be tested under close to physiological 
conditions in whole blood. Adhesion and aggregation can be tested as laminar 
flow with uniform shear stress over an entire plate surface and a covering 
rotating cone is induced. In modified tests different agonists are added to the 
blood samples. Therefore platelets aggregate and do not adhere to the 
polystyrene well as shear stress is applied (Savion and Varon , 2006). 
To test the platelet function (screening test, ST), 130µl of thoroughly mixed 
whole blood (1 Minute on the tube rotator at 10 rpm) were placed central on a 
polystyrene well (plate). For the first six analyses citrated blood (3,2% sodium 
citrate) was used, all following tests were done with heparin blood. Special 
pipette tips were used to reduce preanalytical shear stress to a minimum. 
Immediately after placing a specially developed acrylnitril-butadien-styrene 
cone, together with a bell-housing, on the well, a shear rate of 820 U/min 
(2050s-1) was applied for 120 seconds.  
The wells were then washed thoroughly with tap water and in succession 
stained with May-Grünwald solution for about one minute.  
Samples were analyzed under an inverted light microscope. 7 different surface 
areas were captured from each run and medians of these were calculated by 
the DiaMed Image Analysis software (Galai, Migdal Haemek, Israel).  
The percentage of surface covered (SC, %) and the average size of surface 
bound objects (AS, µm2) gave the required information about platelet adhesion 
(surface coverage) and aggregation (average size). 
42 
 
In healthy subjects single and aggregates of adherent platelets are aligned in 
the direction of the flow. The Impact-R™ ST is not sensitive to Aspirin or 
Clopidogrel induced platelet inhibition (Shenkman et al, 2000).  
For testing agonist induced platelet aggregation (response tests), different 
platelet activating agonists were added to defined aliquots of the blood samples 
(Table 7). After gently mixing the reaction tubes and incubation for one minute 
on the tube rotator at 10 rpm, 130µl of the sample were placed on the well and 
the procedure was subsequently performed as described for the ST.  
For each individual a ST was performed. In population one 1 and 2 additionally 
AA- and ADP-response tests were done. Like Shenkman et al. (2008) only SC 
values were used for testing the response to Aspirin and Clopidogrel in 
population 2.  Furthermore a TRAP (thrombin receptor activating peptide) test 
was done in population 3 and in patients with vWD (population 3) a RISTO L 
test was added. 
Table 7: Impact-R™-Agonists and final Concentrations  
 IMPACT-R™ IMPACT™ 
AGONIST FINAL CONC Aliquot for 0,4 ml FINAL CONC Aliquot for 0,3 ml 
AA 275µM 7µl 320µM 6µl 
ADP 2µM 8µl 1,38µM 3,75µl 
TRAP-6 25µM 10µl 2,5µM 6µl 
RISTO L 1mg/ml 25µl 0,44mg/ml 8µl 
(AA=Arachidonic acid, ADP= adenosine diphosphate, TRAP=Thrombin receptor activating 
peptide, RISTO=Ristocetin, L=low) 
b) DiaMed Impact™ Analyzer 
The Impact™ (DiaMed, Cressier, Switzerland) is a fully automated version of 
the Impact-R™ and was designed to have a POC-device which is easy to 
operate and as safe as possible, so that less experienced operators as in 
intensive care units, emergency rooms or at the patient´s bedside, can also 
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obtain reliable results. In this study the practicability of this newly developed 
apparatus was tested.  
Unlike the Impact-R™ assay, citrated blood (3,8% sodium citrate) was used. 
For testing the effect of the most frequently used anti-platelet drugs with the AA- 
and ADP-response tests DiaMed provided vials with an optimized concentration 
of the respective freeze-dried agonist for direct reconstitution with 300µl blood. 
Other agonists had to be reconstituted with distilled water as for the Impact-R™ 
(Table 7). 
In general Impact™ screening test (regular platelet function test) and agonist 
response tests were conducted in the same way as in the Impact-R™ assay, 
with the difference that blood was pipetted automatically and all steps were 
prompted by the software.  
After the automated staining procedure 32 different surface areas were 
captured and medians of surface coverage (SC, %) and average size of objects 
(AS, µm2) were calculated by the image analyzer. Results were printed out on a 
connected printer. 
A daily quality control (“self test”) was performed before testing.  
For each individual a ST, an AA-response test, and an ADP-response tests 
were performed. Like Shenkman et al. (2008) only SC values were used for 
testing the response to Aspirin and Clopidogrel in population 2.  For population 
1 and 3 additional TRAP- and ristocetin-responses were analyzed. 
c) Impact-R™ wells on Impact™  (IRonI) 
The Impact™ analyzes 32 images while the Impact-R™ uses 7 images. 
For testing the comparability of the Impact-R™ analysis with that of the 
Impact™ 47 Impact-R™ wells in total (14 regular platelet function test wells of 
healthy individuals and 10 of patients and 14 ADP-response test wells of 
healthy individuals and 9 of patients on anti-platelet therapy) were analyzed on 
the Impact™ device. 
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5. PLATELET FUNCTION ANALYZER 
For testing the in-vitro-bleeding time the platelet function analyzer PFA-100® 
(Dade Behring, Marburg, Germany) was used. The system, consisting of an 
apparatus and disposable test cartridges, was designed to identify inherited, 
acquired or induced platelet dysfunction by simulating the mechanism of 
primary haemostasis following a vascular injury in vitro. 
Whole blood is aspirated from a sample reservoir through a capillary and the 
aperture of a membrane (150µm) via a vacuum pump with 40mbar. The 
membrane is coated with 2µg equine Type I collagen as initial matrix for platelet 
adhesion and two different agonists, either 10µg epinephrine bitartrate (Col/EPI 
test cartridge) or 50µg adenosine-5´-diphosphate (Col/ADP test cartridge). At 
the beginning of a test the membrane is wetted with a trigger solution (9% 
aqueous sodium chloride). Through high shear flow conditions (5000-6000/s) 
within the capillary platelets become activated and form a plug subsequently, 
which occludes the membrane aperture. The duration until the blood flow is 
stopped completely is measured and recorded as closure time (CT).  
To detect platelet dysfunction induced by intrinsic platelet defects, vWD or 
exposure to platelet inhibiting agents the Col/EPI test cartridge would be the 
first choice. If an abnormal result is obtained with this cartridge the Col/ADP test 
is used to indicate whether this abnormal result has been caused by the effect 
of COX-inhibitors or medications containing COX-inhibitors.  
In this study 800µl of well mixed citrated blood (3,8% Na-citrate) were pipetted 
into the sample reservoir opening of the test cartridge (warmed-up to room 
temperature for 15 minutes) after placing it in the PFA-100® carousel. After 3-8 
minutes measuring time the result (CT, sec) was printed out by an integral 
printer.  
A daily quality control (“self test”) was performed before sample testing. 
Both Col/EPI-test and Col/ADP test were performed with all specimens of 
population 2 and 3. For population 1 PFA-100® tests were not done, because 
normal ranges had been established in this laboratory on the same device 
recently. 
A list of all reagents used in this study can be found in the Appendix. 
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4. STATISTICS 
All statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS 15.0; Chicago, IL). Descriptive statistics were calculated in the 
form of median and range. For testing correlations between methods 
Spearman´s Rho was calculated. In case of normal distribution Pearson 
Correlation was used (specifically noted in Results). Furthermore a Man-
Whitney-U test was calculated. Two-sided P-values < 0,05 were considered 
statistically significant and highly significant if P < 0,01. Additionally, specificities 
and sensitivities were determined based on the results from LTA and Impact-
R™. 
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IV. RESULTS 
1. NORMAL VALUES 
For each parameter normal ranges were determined in 39 healthy individuals. 
For this purpose minimum and maximum values in the reference population 
were calculated after elimination of extreme values. In addition, data are 
presented as medians.  
For the LTA normal values and medians were obtained for the AA, ADP, TRAP-
6, epinephrine (EPI) and ristocetin (RISTO H) (Table 8). The table shows the 
maximal aggregation (max.amp.), the slope, and the area under the curve (au). 
PRP values were also analyzed to obtain a normal range (Table 8).   
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Table 8: Normal ranges for LTA 
LIGHT TRANSMISSION AGGREGOMETRY 
TEST 
NORMAL 
RANGE Median N 
AA max.amp (%) 67 - 105 90 30 
AA slope 63 - 156 118,5 30 
AA au 198,8 - 415,6 362,75 30 
ADP max.amp (%) 66 - 94 85 29 
ADP slope 88 - 140 107 29 
ADP au 290,7 - 471 361,2 29 
TRAP max.amp (%) 71 - 104 89 30 
TRAP slope 90 - 197 151,5 30 
TRAP au 261,9 - 426,4 387,4 29 
EPI max.amp (%) 69 - 93 84 29 
EPI slope 48 - 99 68 28 
EPI au 124,4 - 369 291,2 29 
RISTO H max.amp (%) 86 - 100 93 29 
RISTO H slope 79 - 199 134 29 
RISTO H au 343,4 - 840 403,5 29 
PRP (G/l) 185 - 411 310 31 
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For the WBA (Multiplate®) normal values were obtained for the following 
agonists: AA (ASPItest), ADP (ADPtest and ADPtest HS), TRAP (TRAPtest) 
and ristocetin (RISTOtest) (Table 9). 
Table 9: Normal ranges for Multiplate® 
IMPEDANCE AGGREGOMETRY (Multiplate®) 
TEST 
NORMAL 
RANGE Median N 
ASPItest (AU) 67 - 147 92 35 
ADPtest (AU) 46 - 134 73 36 
ADPtest HS (AU) 37 - 117 62 31 
TRAPtest (AU) 74 - 156 103 34 
RISTOtest H (AU) 60 - 148 93 31 
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CPA (Impact™ and Impact-R™) normal values and medians for screening tests 
(ST), response tests (AA, ADP), positive control test (TRAP) and additionally 
ristocetin test (RISTO L - only on Impact™) are shown in Table 10.  
Table 10: Normal ranges for CPA 
  IMPACT™ IMPACT-R™  
TEST NORMAL RANGE Median N NORMAL RANGE Median N 
ST SC (%) 7,3 - 16 11 39 5,5 - 18 12 34 
ST AS (µm2) 19 - 41 26 38 24 - 113 43 34 
AA SC (%) 0,3 - 2,8 1,2 39 0,4 - 2,9 1 35 
AA AS (µm2) 22 - 41 30 39 27 - 58 42 34 
ADP SC (%) 0,5 - 3,3 1,6 37 0,3 - 2,1 1,4 32 
ADP AS (µm2) 24 - 59 35 38 31 - 66 46 35 
TRAP SC  (%) 1,5 - 10 5,7 30 0,6 - 2 1,1 9 
TRAP AS 
(µm2) 22 - 45 30 30 32 - 62 42 9 
RISTO L SC 
(%) 1,3 - 4,3 2,9 27 -   - - - 
RISTO L AS 
(µm2) 28 - 52 32 30 -   - - - 
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28 wells were manually prepared and tested on the Impact™–R (ST, ADP), and 
have also been analyzed on the Impact™ system (Table 11).   
Table 11: Normal ranges for Impact-R™ wells analyzed by Impact™  
IMPACT-R™ on IMPACT™ 
TEST 
NORMAL 
RANGE Median N 
ST SC (%) 6,8 - 19 12,5 14 
ST AS (µm2) 25 - 82 38,5 14 
ADP SC (%) 1,1 - 2,3 1,7 14 
ADP AS (µm2) 36 - 62 42,5 14 
 
Normal values for PFA-100® Col/ADP CT and Col/EPI CT, and the VASP assay 
have recently been determined on the same devices as those used in this study 
and therefore no new investigations were done (Table 12).  
Table 12: Normal ranges for PFA-100® and VASP assay 
NORMAL RANGE 
PFA-100® COL/ADP CT (sec) 74 - 120 
PFA-100® COL/EPI CT (sec) 82 - 170 
VASP (%)   > 70 
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Normal values for vWF:AG, vWF:RiCoF and Fibrinogen have not been 
calculated in this study. Values obtained in earlier studies have been used 
(Table 13). 
 Table 13: Normal ranges for vWF:AG, vWF:RiCoF and Fibrinogen 
NORMAL RANGE 
VWF:AG (%)  > 40 
VWF:RICOF (%)  > 40 
FIBRINOGEN  190 - 390 
 
Furthermore normal ranges and medians for WBC were calculated (Table 14). 
Table 14: Normal ranges for WBC  
WHOLE BLOOD COUNT 
TEST NORMAL RANGE Median N 
PLT (G/l) 169 - 354 258 35 
HB (g/dl) 11 - 17,4 14,2 31 
HEMATOCRIT (%) 32,45 - 51,1 40,65 32 
MCV (fl) 77,11 - 104,83 88,1 29 
ERY (T/l) 3,83 - 5,96 4,66 33 
LEUCO (G/l) 4,4 - 10,7 6,84 31 
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2. PATIENTS ON ANTI-PLATELET THERAPY 
 
Based on the reference values for healthy individuals (Tables 8-12) cut-off 
values for patients on anti-platelet therapy were defined to get information about 
their response to Aspirin and Clopidogrel. For the LTA and WBA response was 
defined as values underneath the lower threshold of the reference interval. In 
the other methods (CPA devices (Impact™, Impact-R™), PFA-100®, VASP 
assay) cut-off values were defined as upper threshold of the normal range. 
Values above indicate response. 
 
1. SCREENING TESTS  
(REGULAR PLATELET FUNCTION TESTS) 
A screening test (ST) was only applicable with the Impact™ and Impact-R™. As 
platelet adhesion is not impaired by Aspirin and Clopidogrel, values within the 
normal range can be expected. In this study, three out of 32 patients (9,4%) had 
values outside the normal range for SC, AS values were higher than the normal 
range in two patients (6,3%) on the Impact™. On the Impact-R™ SC values in 
three out of 31 patients (9,7%) were out of the normal range. One out of 9 
(11,2%) Impact-R™-wells-analyzed-on-Impact™ (IRonI) samples showed a 
result which was out of the range obtained in healthy controls.  
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Correlations between Impact™ ST and Impact-R™ ST  
(Figure 12) 
Correlations between Impact™ ST and Impact-R™ ST were calculated, but no 
significant results could be found (SC: r=0,161; p≤0,385; AS: r=0,256; p≤0,150). 
Between Impact™ and IRonI ST no significant correlation was found either (SC: 
r=0,260; p≤0,468; AS: r=0,018; p≤0,960). Only results obtained by Impact-R™ 
showed expected significant and highly significant correlation with results of 
IRonI (SC: r=0,746; p≤0,013; AS: r=0,901; p≤0,0001). Concordant results 
between methods were obtained more often for AS values than for SC values. 
Concerning analysis with IRonI best concordance was found with Impact™ SC 
and Impact-R™ SC, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
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Figure 12: Relationship between Impact™, Impact-R™ , Impact-R™-analyzed-on-Impact™ 
(IRonI) screening tests (st) 
The figure shows scatterplots with recorded vertical and horizontal reference lines (upper and 
lower threshold of the normal range). The central square shows concordance in screening tests 
between methods. Concordant results for Impact™ (I st) and Impact-R™ (I-R st) are shown in 
(a) for SC and in (b) for AS. (c) and (d) show concordance between Impact™ (I st) and IRonI 
SC and AS respectively. Concordant results between Impact-R™ (I-R st) and IRonI for SC and 
AS are shown in (e) and (f).  
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2. RESPONSE TO ASPIRIN 
Cut-off values for response to Aspirin were defined as maximal aggregation < 
67% for LTA, AU < 67 for the Multiplate® and SC > 2,8% for the Impact™,  SC > 
2,9% for the Impact-R™. PFA-100® CT > 170 seconds indicates response in 
this test. Additionally cut-off values for slope (< 63) and au (< 198,8) in the LTA 
were recorded.  
In reference to the obtained normal ranges, response to Aspirin was found in 27 
out of 30 (90%) in the LTA concerning maximal aggregation. On the Multiplate® 
(ASPItest) 28 out of 30 (93, 3%) patients were responders. On the Impact™ all 
patients (32) showed response for SC and on the Impact-R™ 19 out of 31 
(61,3%) showed response for SC. On the PFA-100® 21 out of 30 (70%) patients 
showed sufficient Aspirin effect. Additionally LTA´s au (90%) and slope (63%) 
were considered.   
Sensitivities and specificities of values obtained with all performed AA tests, 
based on the results from LTA (maximal aggregation), were also calculated and 
are shown in Table 15. Based on Impact™, Impact-R™ had a sensitivity of 
61%. 
Table 15: Sensitivities and specificities for AA based on LTA  
LTA AA 
  
MULTIPLATE® 
(AU) 
IMPACT™ 
SC (%) 
IMPACT-R™ 
SC (%) 
PFA-100® 
(sec) 
SENSITIVITY 
(%) 100 100 67 74 
SPECIFICITY 
(%) 67 - 67 67 
 
a) Correlations between AA-LTA and other methods  
(Figure 13) 
There was only a significant correlation between data obtained by LTA and 
Multiplate® (r=0,461; p≤0,01). All other methods did not correlate: Impact™ 
(r=0,-0,069; p≤0,716), Impact-R™ (r=-0,070; p≤0,715) and PFA-100® (r=-0,225; 
p≤0,232). Results obtained by Multiplate® showed a good concordance with 
those obtained by LTA. A good concordance for Impact™ SC with LTA was 
seen, the results with the Impact-R™ were less concordant. In PFA-100® and 
LTA only few patients were responders in both methods.  
a 
 
b 
c 
 
d 
Figure 13: Relationship between AA-LTA and Multiplate®, Impact™, Impact-R™, and PFA-100®  
The figure shows the relationship and concordant results in response to Aspirin (square 
“RESPONDER”) through recorded reference lines (cut-off values) between LTA maximal 
aggregation (A aa amp) and Multiplate® (M aa u) (a), Impact™ (I aa sc) (b), Impact-R™ (I-R aa 
sc), (c), and PFA-100® (P epi sec) (d).  
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 b) Correlations between Impact™ and Impact-R™ AA-response tests  
(Figure 14) 
There was no significant correlation between Impact™ and Impact-R™ AA-
response test (SC: r=0,231; p≤0,212). Good concordance in response between 
methods according to SC was found.  
 
Figure 14: Relationship between Impact™ and Impact-R™ AA-response tests 
The figure shows the relationship between Impact™ (I aa sc) and Impact-R™ (I-R aa sc) results 
and the concordance in response to Aspirin (square “RESPONDER”) through recorded 
reference lines (cut-off values). 
c) Correlations within AA-LTA  
(Figure 15 
Highly significant correlations were found between maximal aggregation and 
slope (r=0,745; p≤0,0001), respectively au (Pearson r=0,797; p≤0,0001). This 
was not surprising, because slope and au values were calculated based on the 
maximal aggregation. However, some patients, who were assigned to 
responders according to maximal aggregation, were no responders in respect of 
the slope. 
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b 
 
Figure 15: Relationship between AA-LTA maximal aggregation, slope and the area under the 
curve   
The figure shows the relationship between LTA maximal aggregation (A aa amp) and slope (A 
aa slope) (a) and the area under the curve (A aa au) (b). The concordance in response to 
Aspirin (square “RESPONDER”) can be seen through recorded reference lines (cut-off values). 
3. RESPONSE TO CLOPIDOGREL 
Cut-off values for response to Clopidogrel were defined as maximal aggregation 
< 66% for LTA, AU < 46 for ADPtest and AU < 37 for ADPtest HS on Multiplate® 
and values > 70% for VASP assay. For the Impact™ SC > 3,3%, for the Impact-
R™ SC > 2,1% and for IRonI SC > 2,3% defined response. The cut-off value for 
Col/ADP is presumed at a CT of 120 seconds. Additionally cut-off values for 
slope (< 88) and au (< 290,7) in the LTA were recorded. 
In reference to the obtained normal ranges, response to Clopidogrel was found 
in 20 out of 23 (87%) patients in the LTA concerning maximal aggregation. 
Values below the cut-off were found only in 7 out of 23 (30,4%) patients for 
ADPtest on Multiplate® but in 19 out of 23 (82,6%) for the “high sensitive” test 
(ADPtest HS). VASP assay had positive results in 19 out of 22 patients 
(86,4%).16 out of 24 patients (66,7%) for SC on the Impact™, 19 out of 23 
(82,6%) on the Impact-R™ and 8 out of 9 for IRonI (88,9%) showed sufficient 
Clopidogrel effect. On the PFA-100® 9 out of 23 patients (39,1%) were 
responders. Additionally LTA slope (39,1%) and au (82,6%) were considered. 
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In the LTA (maximal aggregation) 5 of 6 patients (83,3%) who did not receive 
Clopidogrel but only Aspirin had values below the cut-off for ADP. Furthermore 
two of these patients had low values in LTA slope. One of these patients 
additionally had low values on Multiplate® and also an increased PFA-100® 
value. With the PFA-100® two more patients had abnormal values. 
Sensitivities and specificities of values obtained with all performed ADP tests, 
based on the results from LTA (maximal aggregation), were also calculated and 
are shown in Table 16. Based on Impact™, Impact-R™ had a sensitivity of 93% 
and a specificity of 38%. 
Table 16: Sensitivities and specificities for ADP based on LTA 
LTA ADP 
  
MULTIPLATE® 
(AU) 
MULTIPLATE® 
HS (AU) 
VASP 
(%) 
IMPACT™  
SC (%) 
IMPACT-
R™ SC 
(%) 
PFA-
100® 
(sec) 
SENSITIVITY 
(%) 35 85 85 70 85 45
SPECIFICITY 
(%) 100 33 - 67 33 100
a) Correlations between ADP-LTA and other methods  
(Figure 16) 
Highly significant results between data obtained by LTA and Multiplate® 
(Pearson r=0,571; p≤0,001), Multiplate® HS (r=0,671; p≤0,0001) and Impact™ 
(r=-0,793; p≤0,0001), were found. With Impact-R™ (r=-0,546; p≤0,003) a 
significant correlation could be found. The other methods did not correlate with 
LTA (PFA-100®: r=-0,299; p≤0,115; VASP: r=-0,339; p≤0,123). Best 
concordance in response was found with Impact-R™, followed by Multiplate® 
ADPtest HS, VASP, Impact™, PFA-100® and Multiplate® ADPtest. 
a 
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Figure 16: Relationship between ADP-LTA and Multiplate®, VASP, Impact™, Impact-R™, and 
PFA-100® 
The figure shows the relationship and concordant results in response to Clopidogrel (square 
“RESPONDER”) through recorded reference lines (cut-off values) between LTA maximal 
aggregation (A adp amp) and Multiplate® (M adp u) (a), Multiplate® hs (M adphs u) (b), VASP 
(c), Impact™ (I adp sc) (d), Impact-R™ (I-R adp sc) (e), and PFA-100® (P adp sec) (f).  
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b) Correlations between Impact™ and Impact-R™ ADP-response tests  
(Figure 17) 
Highly significant correlations between SC values obtained with Impact™ and 
Impact-R™ (r=0,790; p≤0,0001) and a significant correlation between those on 
Impact™ and IRonI (r=0,785; p≤0,012) were found. The expected highly 
significant correlation between Impact-R™ and IRonI was also found (r=0,907; 
p≤0,0001). Furthermore concordant results in ADP-response between methods 
were found. 
a 
 
b 
 
c 
 
 
Figure.17: Relationship between Impact™ and Impact-R™ and IRonI ADP-response tests 
The figure shows the relationship and the concordance in response to Clopidogrel (square 
“RESPONDER”) through recorded reference lines (cut-off values) between Impact™ (I adp sc) 
and Impact-R™ (I-R adp sc) in (a), between Impact™ (I adp sc) and IRonI (I-RonI adp sc) in (b) 
and between Impact-R™ (I-R adp sc) and IRonI (I-RonI adp sc) in (c).   
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c) Correlations within ADP-LTA  
(Figure 18) 
Highly significant correlations were found between maximal aggregation and 
slope (r=0,723; p≤0,0001), respectively au (r=0,763; p≤0,0001). This was not 
surprising because slope and au values were calculated based on the maximal 
aggregation. However, according to common response, concordance between 
maximal aggregation values and slope was not particularly good, better results 
were obtained for the correlation with the area under the curve (au). 
 
a      b 
Figure 18: Relationship between ADP-LTA maximal aggregation, slope and the area under the 
curve   
The figure shows the relationship between LTA maximal aggregation (A adp amp) and slope (A 
adp slope) (a) and the area under the curve (A adp au) (b). The concordance in response to 
Clopidogrel (square “RESPONDER”) can be seen through recorded reference lines (cut-off 
values). 
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Table 17 summarizes the response and non-response to Aspirin and 
Clopidogrel by the different methods. 
Table 17: Response and Nonresponse to Aspirin and Clopidogrel 
  
DOUBLE 
RESPONSE 
DOUBLE NON-
RESPONSE 
ASPIRIN 
RESPONSE/ 
CLOPIDOGREL 
NON-RESPONSE 
ASPIRIN NON-
RESPONSE/ 
CLOPIDOGREL 
RESPONSE 
LTA 20 1 2 0 
MULTIPLATE®   7 1 15 0 
MULTIPLATE® 
HS 19 1 3 0 
VASP - 3 - 19 
IMPACT™  16 0 8 0 
IMPACT-R™ 16 2 2 3 
PFA-100® 8 7 7 1 
 
4. TRAP – POSITIVE CONTROL 
In all methods, where the thrombin receptor activating peptide (TRAP-6) was 
used, values were unexpectedly abnormal in some patients. With LTA lower 
values for maximal aggregation were obtained in 56,7% of patients (Z=5,779; 
p≤0,0001) and in 26,7% concerning both slope and au. AU on Multiplate® were 
lower in 27,6% and Impact-R™ SC values were higher in 16 out of 23 patients 
(69,6%) than in healthy controls.  
a) Correlations between TRAP-LTA and other methods  
(Figure 19) 
A significant correlation was found only between LTA (maximal aggregation) 
and Impact-R™ SC (r=-0,486; p≤0,019). Multiplate® values did not correlate (r=-
0,180; p≤0,350). According to concordance in response to TRAP the best result 
was obtained for Impact-R™ SC, followed by Multiplate®. 
 
a 
 
b 
 
Figure 19: Relationship between TRAP-LTA and Impact™, and Multiplate® 
The figure shows the relationship and concordant results through recorded reference lines (cut-
off values) for the positive control between LTA maximal aggregation (A trap amp) and Impact-
R™ SC (I-R trap sc) in (a) and between LTA (A trap amp) and Multiplate® (M trap u) (b).  
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b) Correlations within TRAP-LTA  
(Figure 20 
Highly significant correlations were found for both calculations, maximal 
aggregation with slope (Pearson r=0,731; p≤0,0001) and with au (r=0,746; 
p≤0,0001). 
Despite good correlation, poor concordance in response for both slope and au 
with maximal aggregation was found, as shown in Figure 4.9.  
 a 
 
b 
 
Figure 20: Relationship between TRAP-LTA maximal aggregation, slope and area under the 
curve 
The figure shows the relationship and the concordance in positive results between LTA maximal 
aggregation (A trap amp) and slope (A trap slope) (a) and the area under the curve (A trap au) 
(b).  
Examples of graphs and pictures showing results obtained with LTA (Figure III), 
Impact-R™ (Figure IV) and Multiplate® (Figure V) can be found in the Appendix. 
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3. PATIENTS WITH PLATELET DISORDERS 
This group is described on the basis of the obtained normal values only, no 
statistical analyses were done. For RISTO-LTA L, Multiplate® RISTOtest L, 
Impact-R™ ristocetin test, and COL-LTA, tests no normal range was defined 
because no healthy individuals were tested. 
1. BLEEDING COMPLICATIONS  
In this group 12 patients with bleeding complications were tested. All patients 
showed normal values for vWF:AG, vWF:RiCoF and Fibrinogen.  
In reference to the obtained normal ranges for platelet function tests two 
patients had abnormal values for the ST on Impact™ (one SC higher (9,1%), 
one lower (9,1%)) and on the Impact-R™ one patient (8,3%) showed an 
abnormally high AS value. 
In the AA-LTA 3 out of 11 individuals (27,3%) had values below concerning 
maximal aggregation, one (9,1%) patient  was found above the upper threshold. 
On Multiplate® (ASPItest) 3 out of 7 tested patients (42,9%) showed results 
below the reference range. AA-response tests on the Impact™ were abnormal 
in 6 patients for SC (54,5%; all above the normal range) and in 5 patients for AS 
(4 above (36,4%)  1 below (9,1%)). PFA-100® Col/EPI CT was prolonged in 5 
patients (45,5%). Additionally AA-LTA´s slope and au values were considered 
abnormal (18,2%; 36,4%).  
In the ADP-LTA one out of 11 (9,1%) individuals was below the normal range 
concerning maximal aggregation. On Multiplate® (ADPtest) all 8 tested 
individuals had values within the normal range. ADP-response tests on the 
Impact™ were abnormal only for SC in 3 patients (27,3%; all above the normal 
range). PFA-100® Col/ADP CT was above the normal range in 4 patients 
(36,4%) and below in 1 case (9,1%)., Additionally for ADP-LTA´s slope and au 
abnormal results were found (27,3%; 18,2%).   
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TRAP-LTA showed abnormal results in two patients (one higher, one lower than 
in healthy controls (9,1% each)) concerning maximal aggregation. The 
TRAPtest AU on Multiplate® were within the normal range in all tested 
individuals. TRAP tests on the Impact™ showed one result above and one 
below the normal range for SC (9,1% each). On the Impact-R™ SC values were 
higher in two out of 9 patients (22,2%) and below in one patient for AS (11,1%). 
Additionally TRAP-LTA showed abnormal results in two patients (one higher, 
one lower than in healthy controls (9,1% each)) for both, slope and au.  
With the RISTO-LTA H three out of 11 patients (27,3%) had values below the 
normal range and two (18,2%) had values above the normal range concerning 
maximal aggregation. RISTOtest H on Multiplate® had low values in two 
patients (16,7%). Additionally abnormal results for RISTO-LTA H´s slope and au 
were found (18,2%;9,1%).  
The RISTO L test on the Impact™ was higher than the normal range in 3 
patients (27,3%) and below in 2 patients (18,2%) for SC. AS values were lower 
than in healthy controls in 2 patients (18,2%). On Multiplate® a RISTOtest L was 
performed in 8 patients and also RISTO-LTA L tests were done for each patient 
(n=11) (no reference ranges available).  
With EPI-LTA 3 out of 10 individuals (30%) had values below the normal range 
concerning maximal aggregation, one patient was found above the upper 
threshold (10% each). Additionally EPI-LTA´s slope (2 below (20%), 1 above 
(10%)) and au (10%) values were considered abnormal. For 6 patients COL-
LTA tests were performed (no reference values available).  
2. END STAGE RENAL FAILURE  
In this group 5 patients with end stage renal failure (ESRF) were tested. 4 
patients had Fibrinogen values above the normal range. 
In reference to the obtained normal ranges for platelet function tests two out of 
5 patients had low SC values in the screening test (ST) on Impact™. All other 
ST values (Impact™ and Impact-R™) showed results within the normal range. 
AA-LTA was normal in all tested patients (n=5) with all parameters. On 
Multiplate® (ASPItest) one out of 5 patients was found below the reference 
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range. AA-response tests on the Impact™ were normal in all tested patients 
(n=4). PFA-100® Col/EPI CT was prolonged in 4 patients.  
In ADP-LTA (maximal aggregation) and with Multiplate® ADPtest all 5 tested 
individuals had values within the normal range. On the Impact™ ADP-response 
was below the normal range in one patient for AS. PFA-100® Col/ADP results 
were found abnormal in 4 of 5 patients (three above and one below the normal 
range). Additionally ADP-LTA results for slope and au were considered 
abnormal.  
TRAP-LTA showed low results in two patients (one with maximal aggregation 
and one with slope) TRAPtest on Multiplate® was found below the lower 
threshold in one case. TRAP tests on the Impact™ showed only one result 
below the normal range for AS whereas on the Impact-R™ SC values in all 5 
tested patients were higher than the normal range and below in 4 of 5 patients 
for AS. . 
In the RISTO-LTA H three out of 5 patients had values below the normal range 
with maximal aggregation and one patient additionally showed a low result for 
au. RISTOtest H on Multiplate® was within the normal range in all tested 
individuals.  
The RISTO L test on the Impact™ was lower than the normal range in one 
patient for SC. AS values were lower in three patients. On Multiplate® a 
RISTOtest L was performed only in one patient, RISTO-LTA L tests were done 
for all 5 patients (no reference ranges available).  
With EPI-LTA three out of 5 individuals had values below the normal range 
concerning maximal aggregation. One patient additionally showed a low result 
for slope. Furthermore COL-LTA tests were performed for all 5 patients (no 
reference values available).  
3. VON WILLEBRAND DISEASE  
Two patients (A and B) with diagnosed von Willebrand Disease were analyzed. 
Patient B was tested twice (before and after Haemate (Haemate HS®, Aventis) 
infusion (2000U)).  
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Fibrinogen values were found above the normal range in patient A and in 
patient B after treatment. vWF:AG was below the normal range in patient B 
before treatment, vWF:RiCoF values were low in patient A and patient B before 
treatment. 
Both patients had a very low platelet count (65; 69 and 90 after medication), 
patient B additionally had low hematocrit values (24,9% and 25,6%).  
Therefore Impact™ and Impact-R™ ST values were very low for SC. AS values 
were normal except in patient B after Haemate treatment. 
On both CPA devices (Impact™ and Impact-R™) no AA- and ADP-response 
tests were done. 
AA-LTA was only done for patient B, who showed low results for maximal 
aggregation before treatment and for slope after treatment. With ASPItest on 
Multiplate® both patients showed normal results. PFA-100® Col/EPI CT was 
prolonged in both patients.  
ADP-LTA was only done for patient B, who showed low results for all 
parameters before and for slope and au after treatment. With ADPtest on 
Multiplate® both patients showed normal results. PFA-100® Col/ADP CT was 
prolonged in both patients. 
In the TRAP-LTA low results were obtained with all parameters in patient A, in 
patient B results were low concerning maximal aggregation and au before 
medication, after medication results were found within the normal range. With 
TRAPtest on Multiplate® both patients showed normal results. TRAP tests on 
the CPA devices were only done for patient A. On Impact™ the SC value was 
found below the normal range and on the Impact-R™ the AS value was found 
below.  
In the RISTO-LTA H both patients had low values concerning maximal 
aggregation and au, slope was found below the normal range only in patient B 
after treatment. RISTOtest H on Multiplate® was only low in patient A.  
The RISTO L test on the Impact™ was lower than the normal range only in 
patient A for SC. On Impact-R™, on Multiplate® and in the RISTO-LTA L tests 
were performed in both patients (no reference ranges available). EPI-LTA tests 
were done only with patient B. Slope was higher than the normal range before 
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treatment and below after treatment. For patient B COL-LTA tests were 
performed (no reference values available). 
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V. DISCUSSION 
The prevalence of resistance to the anti-platelet drugs Aspirin and Clopidogrel 
was tested with different methodologies, the “gold standard” LTA, WBA 
(Multiplate®), the VASP phosphorylation assay, CPA (Impact™ and Impact-
R™), and with the platelet function analyzer (PFA-100®). The investigation was 
performed to evaluate these tests and find the most appropriate laboratory 
method. Furthermore, the feasibility of these methods for the assessment of 
inherited, acquired and suspected bleeding disorders was tested. 
 
For the determination of normal values minimum and maximum values were 
used, which have been obtained in healthy controls. However, as there is no 
standardization for testing platelet function by LTA results differ from one study 
to the next. The panel of agonists used in various laboratories is similar, but 
there is no consistency concerning their concentrations (Moffat et al, 2005; 
Jennings et al, 2008). We used agonists´ concentrations as recommended by 
the manufacturer. Further, we used non-parametric tests to obtain reference 
values, as recommended by Hayward et al (2008). Furthermore, platelets 
counts were not adjusted in the PRP, as recommended by Linnemann et al 
(2008) and Cattaneo et al (2007). The response to AA was closest to reports 
from others (Linnemann et al, 2008; Hayward et al, 2008). Data obtained with 
the other agonists like ADP, epinephrine and ristocetin, were difficult to 
compare. They varied widely compared to the other studies (Linnemann et al, 
2008; Hayward et al, 2008), likely due to effects of the differences mentioned 
above but most probably caused by diverse final concentrations used for testing 
aggregation. In this study TRAP-6 was also used as positive control, but this 
agonist is not a commonly used agonist for LTA. Therefore there are no studies 
that report normal values.  
Our normal values obtained with WBA show a wider range when compared to 
the ones obtained by the manufacturer (http://www.Multiplate®.net). This can be 
explained by the smaller sample size in our study, and also by the statistical 
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analyses. We report the range of data, while the reference values provided by 
the manufacturer are based on the 95% confidence interval. 
Normal values for the CPA ST showed greater difference for SC on the Impact-
R™ than on the Impact™ when compared to normal values obtained by the 
manufacturer. Differences in response test results between manufacturer 
normal values and the ones obtained in our study were minimal but showed 
more variability on the Impact-R™ (0,4; 0,7 difference) than on the Impact™ 
(0,5; 0,6 difference). This could be caused by the higher influence of the 
operator on variables affecting the whole procedure, from applying the sample 
onto the polystyrene well to finalizing the staining process or even the 
microscopic analysis on the Impact-R™. A discrepancy of more than ±20% was 
found for almost all results if Impact-R™ was compared with Impact™. Due to 
the use of heparin blood for the Impact-R™ we anticipated higher SC values 
with this instrument than with the Impact™, where citric acid anticoagulated 
blood was applied. Heparin may activate platelets and therefore they may better 
adhere to the surface of the well. However, in most of the cases SC values 
were higher on the Impact™. The higher operator dependency on the Impact-
R™ may explain these findings. We also analyzed the Impact-R™ wells on the 
Impact™ device to see if the number of captured and analyzed pictures 
influences the results. The difference was minimal, however, for both ST and 
the ADP-response test.  
 
In patients on Aspirin, most non-responders were identified by the Impact-R™, 
while interestingly, on the Impact™ all patients showed good response. All other 
methods revealed data within the range of the Impact-R™ and the Impact™.  
By the LTA 90% of patients were responsive to Aspirin in our study. A similar 
prevalence of Aspirin resistance was reported in a variety of studies. 
Lordkipanidze et al (2007) studied patients with stable coronary artery disease, 
Harrison et al (2005) patients after ischemic attack and stroke, and Gum et al 
(2001) just patients from the cardiology ward. All these studies report patients 
with a range of Aspirin dosage from 75 to 325mg/d and the definition of 
response was based on a maximal aggregation <20%. Our patients were on 
100mg Aspirin, and the cut-off value was based on the lower data point 
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obtained in healthy controls, which was 67%. Thus, the definition of cut-off 
values may determine the prevalence of responders.  
By the use of WBA, the frequency of Aspirin resistance in our study was similar 
to findings of Pape et al (2007), but the authors did not disclose the dosage of 
the drug and they used a lower cut-off value (<30AU) than we did (<67AU). 
Furthermore, they used hirudin as an anticoagulant, whereas our samples 
contained heparin. The difference of anticoagulant may explain differences 
between out data and theirs.  
Shenkman et al (2008) reported a similar rate of non-responders on the Impact-
R™ like that obtained in our study.  
If the PFA-100® is used to analyze Aspirin resistance a similar prevalence is 
reported in several studies (Andersen et al, 2002; Gum et al, 2001; Roller et al, 
2002; Harrison et al, 2005). However, the Col/EPI CT is censored and this may 
explain that most studies obtain similar results.  
As the LTA is considered to be the “gold standard” for testing platelet function 
we compared the results of the LTA with those obtained with the other methods.  
Not surprisingly, a significant correlation was obtained with WBA but not with 
any other device. Interestingly, even this correlation was rather poor, but there 
was quite a good concordance for the assignment of responders. Likewise, 
Lordkipanidze et al (2007) reported the best correlation between LTA and WBA 
when comparing different methods in their study. Again, even though 
significant, the reported correlation was rather poor.  
There were no correlations between the CPA and the LTA. Concordance and 
sensitivity were better with the Impact™ than Impact-R™. Shenkman et al 
(2008) report a high similarity between LTA and the Impact-R™ for resistance. 
These findings are in contrast to our data. Again, applying different statistical 
methods may explain this discrepancy. 
There was no correlation between the LTA and PFA-100® and there was also 
no concordance with respect to responders or non-responders. A poor 
correlation or over-all agreement between these methods is reported by several 
studies testing patients on Aspirin only (Lordkipanidzé et al, 2007; Harrison et 
al, 2005; Gum et al, 2001), though varying incidence in non-response was 
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reported. As the PFA-100®, which is widely used for testing Aspirin resistance 
because of its short assay time and simplicity, is a method measuring general 
platelet reactivity, it cannot be expected that all dependent factors are inhibited 
by Aspirin. As this method is non-specific to Aspirin inhibition of COX it might be 
not the best methodology for detecting Aspirin resistance (Lordkipanidze et al, 
2007). 
 
Based on the values obtained in healthy controls, the highest frequency of 
Clopidogrel non-responders was identified by the Multiplate® ADPtest, followed 
by the PFA-100® and the Impact™. With the other methods fewer non-
responders were found.  
Erlinge et al (2008) report about twice as many non-responders with the LTA in 
patients with stable CAD. Other than in our study, they tested on defined days 
after administration of 600mg loading dose. Furthermore, LTA was performed 
with only 5µM ADP and a lower cut-off value was used. Paniccia et al (2007) 
also report higher incidence of residual platelet reactivity in high risk patients, 
although using a very similar concentration and cut-off value. This discrepancy 
may be due to a smaller and less clearly defined population in our study.  
With the WBA more than twice as many responders where found with the “high 
sensitive” test in comparison to the “normal” ADP test, which is similar to the 
findings of Mueller et al (2007).They tested TI-blood samples of patients with 
manifest CAD on Clopidogrel therapy for at least 10 days. Platelet aggregation 
was found to be significantly higher in patients on concomitant treatment with 
Calcium Channel Blockers (CCB) (Siller-Matula et al, 2008). Unfortunately, we 
have no information on concomitant drugs in our cohort.  
Erlinge et al (2008) found about 50% poor responders with the VASP assay in 
their study, even though they used a lower cut-off value. They tested platelet 
inhibition on defined days after administration of a loading dose and daily 
treatment. Based on our method of evaluation, we had only 14% of non-
reponders. It has been shown, that non-responders prevail in diabetic patients 
(Erlinge et al, 2008). We have no information on concomitant diseases in our 
patients, and therefore were not able to stratify our data accordingly. 
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Unlike previous investigations with the CPA, we based the response on data 
obtained in healthy controls, who were not on anti-platelet therapy. Matetzky et 
al (2004), and Gremmel et al (2009) based their interpretation of response on 
the first quartile of data of the total patient population. Therefore, the response 
rate defined by our method and that used by the other investigators is not 
comparable.  
Using the PFA-100® we would assume a low frequency of responders. It has to 
be considered, that the Col/ADP CT test is relatively insensitive to Clopidogrel 
induced platelet inhibition, however (Hayward et al, 2006).  
The LTA correlated more often with the other ADP-response tests than with the 
Aspirin response tests.  
Multiplate® ADPtest results correlated highly significant, but still poor with the 
LTA in our study. Similar data were obtained by Gremmel et al (2008), and also 
Lordkipanidze et al (2008) report comparable results between WBA and LTA, 
although using different concentrations of agonist for both methods. Their WBA 
method, however, differed from our Multiplate®. Sibbing et al (2008) used 
different concentrations for the LTA, but reported a better correlation with the 
WBA. However, their study results were obtained by combining data from 
before and after Clopidogrel treatment and are thus not comparable with our 
data. With the “high sensitive” ADPtest, the correlation was stronger, more 
concordance between results, and a higher sensitivity was obtained. The 
specificity, however, was poor based on LTA.  
In contrast to Gemmel et al (2008) and Paniccia et al (2007), we found no 
correlation between the VASP assay and the LTA. This leads to the assumption 
that the size and the formation of the study population might play a role.  
Both CPA devices showed a significant correlation between LTA and SC. 
Gremmel et al (2009) found a weaker correlation, but similar concordance. Still, 
we obtained a higher sensitivity but a lower specificity than these authors. As 
they tested under similar conditions, differences may be explainable with the 
smaller size of the study population or the strong user dependency with the 
Impact-R™. Shenkman et al (2008) found similar results as Gremmel et al 
(2009), although other final concentrations and cut-off values for the Impact-R™ 
were used.  
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There was no correlation between the PFA-100® and the LTA. Lordkipanidze et 
al (2008) report highly significant correlation, but with a similar poor correlation 
coefficient. The difference may be explained with the differing sample size or 
differing concentrations in the LTA. Paniccia et al (2007) used a similar 
concentration in the LTA as we did and also found no correlation but higher 
concordance in their patients with CAD. As mentioned above, it has to be 
considered that the Col/ADP test is known not to be very sensitive to detect 
Clopidogrel induced platelet inhibition.  
 
According to our results, evaluating the newly developed devices in comparison 
to the LTA, the Multiplate® system (WBA) and the CPA devices seem to be the 
most adequate methods for testing the response to anti-platelet agents.  
 
Results for ST (SC) by Impact-R™ and Impact™ were similar in cardiologic 
patients. We observed larger differences, however, with AA- than with ADP-
response tests if the two devices were compared. Handling of the prefilled 
agonists may explain these findings, at least in part. Correlation calculations 
support these findings, as a good correlation was found between ADP-response 
tests, concordance of results was high, resulting in a high sensitivity for Impact-
R™ results based on Impact™ data. AA-response tests showed no correlation. 
The microscopic analysis of Impact-R™ wells on the Impact™ showed more 
similarity in the ST than in the ADP-response test. Highly significant correlation 
and good concordance were found as expected. 
 
Interestingly, in all methods where TRAP-6 was used in cardiologic patients, 
values were found abnormal in up to about 70%. According to the “Multiplate® 
platelet function analysis – application and interpretation – folder” (Calatzis et 
al) lower values were found in patients treated with anti-platelet agents than in 
healthy blood donors. This might indicate an influence of anti-platelet drugs on 
the response to TRAP, which leads to the question if it is suited as a positive 
control test.  
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Patients with suspected bleeding disorders were also tested with the different 
methods. Due to the small sample size only the incidence of abnormal values is 
discussed in comparison to values obtained in our healthy subjects.   
The most obvious finding in this study group was a relatively high prevalence of 
abnormal results with AA in all tests. As these patients were tested for 
suspected bleeding tendency, these results could be an indicator that Aspirin or 
other COX–1 pathway inhibiting agents have been taken before blood sampling. 
Many people do not consider Aspirin as a mentionable medication. However, 
also with other agonists patients showed abnormal values, which might indicate 
a correlation with an actual bleeding disorder as Hayward et al (2009) report for 
LTA. Furthermore, this group showed the fewest abnormal values for all 
agonists with the WBA, which could be an indication for a relatively low 
sensitivity of this device to identify mild bleeding disorders. However, the PFA-
100® showed abnormal values for almost half of the patients with both 
cartridges. Indeed, the PFA-100® is the most frequently used instrument to 
screen for bleeding disorders (Jennings et al, 2008). The most prevalent 
bleeding disorder in our population is vWD. The PFA-100® was designed to 
detect this inherited disorder, and it may therefore be, that some of our patients 
indeed suffered from mild bleedings due to vWD. 
In patients with ESRF similar tendencies can be found, when comparing 
methods. The PFA-100®, again, shows a relatively high incidence of abnormal 
values, whereas with the Multiplate® fewer patients had abnormal test results. 
The occurring AA abnormalities as found in patients with bleeding complications 
were not prevalent in this group. 
For both patient groups, Multiplate® followed by Impact™ revealed the closest 
concordance with the LTA.  
Although the LTA is known to be a method which tests platelet function under 
relatively unphysiological conditions, it is suitable for the diagnosis of inherited 
platelet function disorders, because it shows characteristic patterns (Budde, 
2002). Comparing the traditional method with the new tests in our vWD patients, 
no clear tendency for the closest similarity could be found, also because of the 
small sample size. With both CPA devices low SC values, but no abnormal AS 
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values were obtained in any of the three samples, which is concordant with 
findings of Varon and Savion (2006) in patients with vWD. 
 
In conclusion, the results of our study were similar to earlier findings, especially 
for Aspirin resistance. Evaluating the different newly developed methods, the 
impedance aggregometry on the Multiplate® device and the CPA are 
considered to be the most adequate methods for testing anti-platelet drug 
response. However, the Multiplate® is maybe not sensitive enough for the 
assessment of mild bleeding disorders. Further investigations with a higher 
quantity of patients are required because the small sample size of our study 
makes it difficult to draw definitive conclusions. 
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VII. APPENDIX 
1. REAGENTS  
Test/ Instrument Reagent Company 
Impact™ Impact™ Test Kit Diamed; www.diamed.com 
  AA-Response Test Diamed; www.diamed.com 
  ADP-Response Test Diamed; www.diamed.com 
  DiaRistin Diamed; www.diamed.com 
  TRAP-6 Bachem;www.bachem.com 
Impact-R™ Impact-R™ Test Kit Diamed; www.diamed.com 
  DiaChidon Diamed; www.diamed.com 
  DiaAdin Diamed; www.diamed.com 
  DiaRistin Diamed; www.diamed.com 
  TRAP-6 Bachem;www.bachem.com 
PFA-100® Collagen/Epinephrine 
(Col/EPI) Test Cartridge 
Dade Behring; www.dadebehring.com 
  Collagen/ADP (Col/ADP) Test 
Cartridge 
Dade Behring; www.dadebehring.com 
   Trigger Solution Dade Behring; www.dadebehring.com 
LTA DiaChidon Diamed; www.diamed.com 
  DiaAdin Diamed; www.diamed.com 
  DiaNephrin Diamed; www.diamed.com 
  DiaRistin Diamed; www.diamed.com 
  DiaColgen Diamed; www.diamed.com 
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  TRAP-6 Bachem;www.bachem.com 
Multiplate® ASPItest Dynabyte; www.Multiplate®.net 
  ADPtest  Dynabyte; www.Multiplate®.net 
  PGE1 Dynabyte; www.Multiplate®.net 
  TRAPtest Dynabyte; www.Multiplate®.net 
  RISTOtest Dynabyte; www.Multiplate®.net 
VASP PLT/VASP/P2Y12  BioCytex; www.biocytex.fr 
 
2. ABBREVIATIONS 
AA arachidonic acid 
ADP adenosine diphosphate 
AS average size 
AU aggregation units 
au area under the curve 
AvWS acquired von Willebrand syndrome 
BSS Bernard-Soulier syndrome 
BT bleeding time 
CAD coronary artery disease 
cAMP cyclic adenosine monophosphate 
COL collagen 
COX-1 cyclooxygenase-1 
CPA cone and plate(let) analyzer 
CT closure time 
EPI epinephrine 
ESRF end stage renal failure 
FITC fluorescein isothiocyanate 
GP glycoprotein 
GT Glanzmann thrombastenia 
H high 
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HS high sensitive 
IRonI Impact-R™ wells on Impact™ 
L low 
LTA light transmission aggregometry 
MACE major adverse cardiac events 
max.AMP maximal aggregation 
MI myocardial infarction 
PFA platelet function analyzer 
PGE1 prostaglandin E1 
PGH2 prostaglandin synthetase 
PLT platelet 
POC point-of-care 
PPP platelet poor plasma 
PRI platelet reactivity index 
PRP platelet rich plasma 
RISTO ristocetin 
SC surface coverage 
ST screening test 
STEMI ST-segment-elevation acute  
 myocardial infarction 
TI thrombin inhibitor 
TRAP thrombin receptor activating peptide 
TXA2 thromboxane A2 
TXB2 thromboxane B2 
VASP vasodilatator-stimulated  
 phosphoprotein 
vWD von Willebrand disease 
vWF von Willebrand factor 
vWF:AG vWF antigen 
vWF:RiCoF vWF ristocetin cofactor 
WBA whole blood impedance  
 aggregometry 
WBC whole blood count 
3. Examples of graphs and pictures  
Examples of graphs and pictures showing results obtained with LTA (Figure III), 
Impact-R™ (Figure IV) and Multiplate® (Figure V) 
 
  
Figure III: LTA graphs of a patient on anti-platelet therapy (left) and of a healthy control (right) 
The figure shows graphs obtained with the LTA. Left: indicating good response to Clopidogrel 
(blue) and Aspirin (black), positive control TRAP (red). Right: Strong aggregation with all 
agonists: ADP (blue), AA: (black), EPI (red), TRAP (green) 
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Figure IV: Pictures of the microscopic analysis on Impact-R™ (AA-response tests) of patients 
on anti-platelet therapy 
The figure shows pictures of the microscopic analysis on Impact-R™, indicating good response 
(SC 9%) (left) and non-response to Aspirin (SC 1,9%) (right) 
 
  
Figure V: Graphs obtained with the Multiplate® ADPtest of patients on anti-platelet therapy 
The left picture shows good response to Cloidogrel (23 AU) while the right picture shows results 
indicating Clopidogrel resistance (73 AU).  
95 
 
96 
 
VIII. CURRICULUM VITAE 
 
Martina Leitner 
Hadikgasse 118/8 
1140 Wien 
T: 0650/4758591 
martina_leitner@gmx.at 
Persönliche Daten: 
Geburtstag: 23.April 1975 
Geburtsort: Wien   
Familienstand: ledig 
  
Ausbildung: 
1980 – 1993   Volksschule und Mittelschule in Linz und Wels 
1994 – 1997   Schule für den medizinisch-technischen Fachdienst,  
AKH Linz 
1998 – 2000  WIKURG für Berufstätige in Graz, Matura 
2001 – 2009  Studium der Humanbiologie (Humangenetik), Universität 
Wien 
Diplomarbeit: 
2007 – 2009 “Evaluation of Laboratory Methods for Testing Anti-Platelet 
Drug Resistance” 
Medizinische Universität Wien, Universitätsklinik für 
Blutgruppenserologie und Transfusionsmedizin 
 
Berufliche Tätigkeiten: 
1997 – 2001  Ordination Dr. Martin Hoff, Graz 
2000 – 2001  Sanatorium Dr. Hoff, Graz 
2005 – 2006  An der Grub Bio Research GmbH 
  
 
 
Wien, im März 2009 
